Optimal management for alcoholic liver disease: Conventional medications, natural therapy or combination? by Kim, MS et al.
Moon-Sun Kim, Madeleine Ong, XianQin Qu, School of 
Medical & Molecular Biosciences, University of Technology 
Sydney, NSW 2007, Australia
Moon-Sun Kim, Faculty of Pharmacy, University of Sydney, 
NSW 2006, Australia
Author contributions: Qu X, Kim MS and Ong M contributed 
to writing the manuscript. Kim MS produced the figures and 
Ong M thoroughly edited the manuscript
Conflict-of-interest statement: No conflict of interest.
Open-Access: This article is an open-access article which was 
selected by an in-house editor and fully peer-reviewed by external 
reviewers. It is distributed in accordance with the Creative 
Commons Attribution Non Commercial (CC BY-NC 4.0) license, 
which permits others to distribute, remix, adapt, build upon this 
work non-commercially, and license their derivative works on 
different terms, provided the original work is properly cited and 
the use is non-commercial. See: http://creativecommons.org/
licenses/by-nc/4.0/
Correspondence to: Xianqin Qu, PhD, MD, School of Medical 
& Molecular Biosciences, University of Technology Sydney, PO 




Received: April 28, 2015
Peer-review started: May 5, 2015
First decision: June 23, 2015
Revised: July 7, 2015
Accepted: November 13, 2015 
Article in press: 
Published online: January 7, 2016
Abstract
Alcohol consumption is the principal factor in the 
pathogenesis of chronic liver diseases. Alcoholic liver 
disease (ALD) is defined by histological lesions on the 
liver that can range from simple hepatic steatosis to 
more advanced stages such as alcoholic steatohepatitis, 
cirrhosis, hepatocellular carcinoma and liver failure. As 
one of the oldest forms of liver injury known to humans, 
ALD is still a leading cause of liver-related morbidity 
and mortality and the burden is exerting on medical 
systems with hospitalization and management costs 
rising constantly worldwide. Although the biological 
mechanisms, including increasing of acetaldehyde, 
oxidative stress with induction of cytochrome p450 
2E1, inflammatory cytokine release, abnormal lipid 
metabolism and induction of hepatocyte apoptosis, 
by which chronic alcohol consumption triggers serious 
complex progression of ALD is well established, there 
is no universally accepted therapy to prevent or 
reverse. In this article, we have briefly reviewed the 
pathogenesis of ALD and the molecular targets for 
development of novel therapies. This review is focused 
on current therapeutic strategies for ALD, including 
lifestyle modification with nutrition supplements, 
available pharmacological drugs and new agents that 
are under development, liver transplantation, application 
of complementary medicines, and their combination. 
The relevant molecular mechanisms of each con-
ventional medication and natural agent have been 
reviewed according to current available knowledge in 
the literature. We also summarized efficacy vs  safety on 
conventional and herbal medicines which are specifically 
used for the prevention and treatment of ALD. Through 
a system review, this article highlighted that the 
combination of pharmaceutical drugs with naturally 
occurring agents may offer an optimal management for 
ALD and its complications. It is worthwhile to conduct 
large-scale, multiple centre clinical trials to further prove 
the safety and benefits for the integrative therapy on 
ALD.
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Core tip: The aim of this article is to review the 
impairment of hepatocellular dysfunction in alcoholic 
liver diseases and their prospective managements. 
Specifically, we focused on the natural therapies 
with their efficacies and safeties. Moreover, we 
summarized molecular mechanisms of herbal therapy 
to treat alcoholic liver disease (ALD). With evidence-
based natural therapy, this article highlighted that the 
combination of pharmaceutical drugs with naturally 
occurring agents may offer an optimal management for 
this complex liver disease. It is worthwhile to conduct 
large-scale, multiple centre clinical trials further to 
prove the safety and benefits for the integrative 
therapy on ALD.
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INTRODUCTION
Alcohol is a psychoactive substance and has been 
widely used in many cultures for centuries. Alcoholic 
abuse causes a large range of diseases and is also 
a social and economic burden in world societies. 
Reduction of alcohol consumption is now becoming 
the global strategy, with attempts to define “harmful 
use” of alcohol by the World Health Organization 
(WHO) to reduce the associated morbidity and 
mortality. Alcohol intake is a principal etiological 
factor in chronic liver diseases. Alcoholic liver 
disease (ALD), which initially manifests as hepatic fat 
accumulation, followed by an inflammatory response 
to induce final stage liver failure, is now a deleterious 
health problem[1]. Alcohol abuse accelerates various 
types of liver diseases, such as alcoholic fatty liver 
disease (AFLD), alcoholic steatohepatitis, alcoholic 
hepatitis (AH), progressive fibrosis, liver cirrhosis 
and liver failure[2]. Patients with ALD, especially with 
alcoholic cirrhosis, are associated with increased risk 
of hepatocellular carcinoma (HCC)[3,4]. 
The prevalence of ALD has increased in the last 
years, parallel with the increasing alcohol consumption 
in the western world as well as in Asian counties[5]. 
According to the WHO report in 2011, chronic alcohol 
consumption results in approximately 2.5 million deaths 
each year with much of the burden related to ALD[6]. 
Though ALD significantly contributes to the rising 
morbidity and mortality statistics and related health 
expenses, there is a lack of effective treatments for 
ALD, especially cirrhosis and HCC. Abstention from 
alcohol may reverse the early stage of ALD to a normal 
condition. The treatment for ALD with conventional 
medicines, mainly pharmaceutical medications, has 
limited success with side-effects. Recently, natural 
medicines, which mainly apply herb-derived agents, 
are emphasized as alternative therapies to manage the 
various alcohol-related liver diseases. It is the aim of 
this article to provide an overview of understanding the 
mechanisms of ALD, which could generate therapeutic 
interventions with conventional medicines, natural 
therapies and their combinations to reverse or retard 
the progression of ALD. 
Pathogenesis of ALD is multifactorial. Strategically, 
the liver is the most important organ to target as about 
90% of alcohol intake is metabolized by the liver[7]. 
Alcohol consumption can cause fatty liver by disrupting 
hepatic lipids and glucose metabolism. Furthermore, 
ethanol and its oxidative and non-oxidative metabolites 
have direct toxic effects on the liver[8]. Histologically, 
fatty liver, or HS, is a malfunctioned fat accumulation 
in the parenchymal cells of the liver. HS is a reversible 
lesion. Fibrosis (or scar formation) is the subsequent 
result if liver injury persists. Fibrosis determined by 
biopsy increases the likelihood of progression to cirrhosis 
and end-stage liver disease. Biochemically, alcohol 
abuse contributes to a serious complex phenomenon 
involving different molecular and biological mechanism 
to induce ALD. Many hypotheses have been investigated 
and established to explain the pathogenic mechanisms 
of ALD. These include: (1) activation of alcohol 
dehydrogenase (ADH) and aldehyde dehydrogenase 
(ALDH) to cause the over generation of acetate[9]; 
(2) induction of cytochrome P450 2E1 (CYP2E1) for 
alcoholic oxidative stress and hepatotoxicity[10]; (3) 
abnormal lipid metabolism by increasing fatty acid (FA) 
synthesis and decreasing of FA oxidation[10]; (4) hepatic 
inflammation indicated by an increase of tumour 
necrosis factor-α (TNF-α) and cytokine release[11]; (5) 
induction of hepatocyte apoptosis and subsequent 
activation of Kupffer cells; (6) increased hepatic levels 
of cellular fibronectin and tissue growth factor-β (TGF-β) 
related to the activation of hepatic stellate cells[12]; and 
(7) ethanol-induction of gut endotoxins[13,14]. Proposed 
mechanisms impacting hepatocellular dysfunction 
by alcohol exposure within ALD pathogenesis are 
summarized in Figure 1. To further improve current 
strategies for managing ALD, a deeper understanding of 
the pathomechanisms of the disease is needed. Various 
curative approaches based on these mechanisms could 
prevent the progression of ALD and its downstream 
sequelae.
CURRENT MANAGEMENT FOR ALD
General management of ALD should initially be 
abstinence from alcohol[2]. This becomes increasingly 
2 January 7, 2016|Volume 22|Issue 1|WJG|www.wjgnet.com
Kim MS et al . Optimal management for alcoholic liver disease
vital as the condition progresses. However, this is largely 
dependent on patient willingness and compliance. 
Currently, there is no universally accepted therapy to 
prevent or reverse the progression of ALD. Successful 
managements include lifestyle modification with the 
correction of nutritional deficiencies, conventional drugs, 
liver transplantation, application of complementary 
medicines, and their combinations[15,16].
Lifestyle intervention
Lifestyle intervention initially entails the abstinence from 
alcohol. Abstinence limits the development of hepatic 
steatosis (HS) and prevents further ongoing liver injury, 
fibrosis and the possibility of HCC. It was reported that 
abstaining from alcohol improves the prognosis of ALD 
patients and prevents advancement to hepatic cirrhosis 
by reducing portal pressure and histological lesions[17,18]. 
However, long-term alcohol abstinence heavily relies on 
patient compliance and willingness and therefore may 
need to be accompanied with psychological therapy 
or social support. Cognitive behavioral therapy, one 
of the psychotherapies, reduces the risk of alcoholism 
and motivates patients to take responsibility and avoid 
relapse[19]. Pharmacotherapy in combination with 
psychosocial interventions also encourages patients 
to sustain abstinence from alcohol. Naltrexone and 
Acamprosate have been used to manage alcohol 
abuse in chronic heavy drinkers[20]. Disulfiram has also 
been approved by the FDA for the management of 
alcoholism and is broadly utilized despite unclear results 
from clinical trials[21]. Disulfiram is an acetaldehyde 
dehydrogenase inhibitor and may cause an increase 
of serum acetaldehyde by changing the alcohol 
metabolism. Disulfiram, therefore, needs to have 
supervised administration[21]. Furthermore, reducing 
alcohol consumption, but not completely stopping has 
also displayed favourable results for the survival of 
patients with ALD[22]. Other important lifestyle changes 
can include smoking cessation, adopting a balanced 
diet and weight control if relevant. Smoking is an 
independent risk factor for increasing the severity 
of ALD and its progression to fibrosis and HCC[23,24]. 
Obesity is another risk factor that can accelerate the 
progression of ALD as it alone is linked to fatty liver 
disease and cirrhosis[25]. 
Nutritional supplements
Malnutrition is another major complication of ALD 
as poor dietary intake from anorexia, vomiting, mal-
digestion, iatrogenic causes, metabolic disturbance, 
hypermetabolic state, impaired protein synthesis, or 
mal-absorption can lead to malnutrition and contribute 
to the disease[26,27]. Nutritional supplementation 
may address calorie, protein, and nutrient intake to 
support hepatocyte regeneration[28]. Protein energy 
malnutrition can be detected with symptoms of 
muscle wasting, edema and loss of subcutaneous 
fat. It is recommended that patients with ALD have a 
daily intake of 1.5 g/kg and 35-40 kcal/kg per day of 
protein[29]. Supplementation with vitamins such as folate 
and thiamine should be considered if their deficiencies 
are detected[16,30]. A discussion concerning micronutrient 
supplementation is necessary beyond the scope of 
this article. Nevertheless, an example of micronutrient 
deficiency related to ALD is seen in zinc deficiency as 
zinc supplementation has shown to improved ALD by 
enhancing the activity of ADH and suppressing CYP2E1 
in animal models[31,32]. In summary, nutritional status 
should be balanced in individual cases of malnutrition. 
Established conventional therapies for ALD
Although patients living with ALD are mostly treated 
with strategies to encourage abstinence from alcohol, 
some patients may need to be accompanied with 
pharmacological treatment approaches. There are 
several drugs that have been widely used and reviewed 
with efficacy, molecular mechanisms (Figure 1), and 
safety. Table 1 summarizes the effects and mechanism 
of conventional medicines.
Corticosteroids were one of the first pharmacologic 
therapies investigated for the treatment of AH and 
many researchers have extensively studied their use 
for patients with ALD[33]. The underlying mechanism of 
action is thought to be the ability of corticosteroids to 
ameliorate the characteristic inflammatory response 
by decreasing TNF-α, IL-6, and IL-8[34,35] and also 
to suppress the formation of acetaldehyde adduct 
metabolites with inhibition of collagen[36]. Prednisolone, 
belonging to the corticosteroid family, with a dose of 
40 mg/d for 28 d followed by tapering over 2-4 wk is 
recommended to treat severe alcoholic hepatitis (AH). 
Another recent published clinical trial randomized 101 
acute AH patients to corticosteroids (e.g., prednisone 
30 mg/d or methylprednisone 24 mg/d intravenously) 
and at 30 d, survival was 70% in corticosteroid group 
when compared to the control (37/53)[37]. Although, 
corticosteroids have been established as a common 
treatment for ALD, the data on treatment duration 
and efficacy of corticosteroids in ALD are conflicting. 
Long-term usage of corticosteroid seems to enhance 
the efficacy while others have showed no benefit 
of corticosteroid therapy after more than 6 mo[38]. 
Glucocorticoid has been demonstrated to decrease 
serum bilirubin levels, which is shown to be a clinically 
useful indicator[39,40]. Using corticosteroids in severe 
AH, however, carries contraindication including sepsis, 
hepatitis B, hepatorenal syndrome and gastrointestinal 
(GI) bleeding[37,41].
Pentoxifylline (PTX), has been thought of as 
an appropriate substitute to replace corticosteroid 
treatment in patients with severe AH when there 
is a contraindication to steroids and is suitable for 
short-term use[42,43]. The exact mechanism of PTX is 
not entirely clear. Anti-TNF actions may explain part 
of its protective effect for ALD. Interesting results 
have proved that 100 to 1000 µg/mL of PTX inhibited 
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methyl donor and contributes in the synthesis of 
the major cellular antioxidant, glutathione (GSH). 
In patients with AH and cirrhosis, decreased hepatic 
SAM, cysteine, and GSH levels caused by abnormality 
of hepatic gene expression in methionine and GSH 
metabolism is observed[48]. SAM deficiency arises in 
early stages of ALD. SAM supplementation can however 
increase reduced SAM concentrations and reverse 
liver injury and mitochondrial damage[49]. SAM works 
to reduce the severity of oxidative stress and hepatic 
stellate cell (HSC) activation by inhibiting hepatic TGF-α 
signalling pathway in an ethanol-lipopolysaccharide-
induced fibrotic rat model[50]. SAM supplementation 
has also shown its benefit in 220 patients with chronic 
hepatitis and cirrhosis in a prospective, double-blind, 
placebo-controlled trial. Other studies have contradicted 
these findings, as one demonstrated that there was no 
TNF expression by murine peritoneal exudate cells 
treated with endotoxin 1 µg/mL and PTX treatment 
significantly reduced serum TNF-α levels in murine in 
vivo[44]. Despite these positive efficacies, treatment 
with PTX still remains controversial. It has been 
reported that no significant differences between 
PTX and corticosteroid treatment groups, or their 
combination were observed[45]. Meta-analysis also 
argued that PTX decreased the hepatic-related 
mortality, but trial sequential analysis did not 
support this result[46]. Nevertheless, the European 
Association for the Study of the Liver and the American 
Association for the Study of Liver Diseases have both 
recommended that PTX should be considered when 
AH patients have contraindications to corticosteroid 
treatment[47].
S-adenosyl-L-methionine (SAM) operates as a 
Figure 1  The molecular mechanisms of alcohol-related liver pathogenesis and therapeutic targets. This figure is adapted from references[8,13,159]. When 
alcohol intake is chronic and heavy, alcohol oxidation occurs via cytochrome P450s, resulting in increased levels of CYP2E1, which in turn causes oxidative stress 
through the generation of ROS which are responsible for lipid peroxidation and alcoholic liver injury. ROS also negatively regulates the activation AMPK and leads to 
overexpression of SREBP-1, resulting in an increase of de novo lipogenesis. GSH also has been reported to its depletion by CYP2E1 followed by the development 
of oxidative stress. Alcohol consumption negatively affects adiponectin secretion from adipocytes then causes inactive AMPK pathway, leading to elevated de novo 
lipogenesis and inflammatory process in the liver, while simultaneously decreasing fatty acid β-oxidation and contributing to hepatocyte necrosis. The red, italicised 
font indicates the end-point of pathology in the liver. ACC: Acetyl-CoA carboxylase; ADH: Alcohol dehydrogenase; AdipoR1: Adiponectin 1; ALDH: Acetaldehyde 
dehydrogenase; AMPK: 5’ adenosine monophosphate-activated protein kinase; CYP2E1: Cytochrome P450 2E1; CPT-1: Carnitine palmitoyl-transferase-1; 
ECM: Extracellular matrix; FA: Fatty acid; GSH: Glutathione; HSC: Hepatic stellate cells; IRF-3: Interferon regulatory factor 3; IL-6/IL-1: Interleukin 6 and 1; LPS: 
Lipopolysaccharide; NADH/NAD+: Nicotinamide adenine dinucleotide hydrogen, nicotinamide adenine dinucleotide; NF-κB: Nuclear factor kappa; ROS: Reactive 
oxygen species; RNS: Reactive nitrogen species; PPAR-α: Peroxisome proliferator-activated receptor-α; SIRT1: Sirtuin 1, SREBP1: Sterol regulator element binding 
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Table 1  The information of effects of current conventional medicines on the treatment of alcoholic liver disease
Medicine/
compound
Type of model Dosage/duration Effects Mechanisms Ref.
Corticosteroid RCT in severe AH Prednisone (30 mg/d, 30 d) Lower mortality AH group 
compared to antioxidant 
treated group
[37]
RMT and double blind trials in 
severe AH
Methylprednisolone (32 mg 
within 7 d) and 28 d treatment 
and then tapered over 2 wk and 
discontinued
Decrease short-term mortality 
of patients with AH
[160]
Pentoxifylline A double-blind, placebo-
controlled trial
400 mg orally 3 times daily for 4 
wk
Decrease in the risk of 
Progressing hepatorenal 
syndrome; 
Improve short-term survival in 
patients with AH
[42]
A RCT followed by open study 
in severe AH
patients
400 mg/d, orally for 4 wk and 
then tapered by  mg/wk for 7 
wk
Better reduced mortality 
compared to prednisolone in 
AH
[161]
SAM Ethanol-LPS-induced fibrotic 
rats
10 mg/kg bw, i.p. Attenuate oxidative stress and 
HSC activation




controlled trial in 220 patients 
with AH and cirrhosis
1600 mg/d orally Decreased serum markers of 
cholestasis; 
Improved subjective 
symptoms such as pruritus, 





C7BL/6J mice with ethanol 
(27.% of total calories)
0.1% Wy-14643 for 4 wk Decreased serum and hepatic 
fat accumulation
Enhancement of hepatic FA 
oxidation pathway;
Increased PPAR-α mRNA 
expression by -fold
[163]
C7BL/6J mice with 4 % 
ethanol (Ethanol feeding for 12 
wk)
Wy-14643 (0 mg/kg per day) 
for last 2 wk
Decreased serum AST and 
ALT.
Dropped on score of hepatic 
steatosis and hepatocyte 
ballooning.
Repress PI3K and COX-2 
expression;
Enhance adiponectin and 
HO-1;
Increase SIRT1 protein 
expression
[164]
C7BL/6J mice with ethanol 
containing diet
(29% of total calories)
Rosiglitazone (3 mg/kg bw/d)
for 2 wk
Reduced hepatic triglyceride 
content; Reduced AST and 
ALT
Upregulated level of 






PAI-1 knockout with ethanol (6 
g/kg i.g.)
200 mg/kg i.p. for 4 d prior to 
ethanol administration
Reduced ALT; 
Prevented hepatic fat 
accumulation
Prevention of the upregulation 
of PAI-1
[7]
Metadoxine HepG2, CFSC-2G and HSC 
treated with ethanol (0 mM) 
and acetaldehyde (17 µM)
10µg/mL for 24 h Reduced peroxidation and 
oxidized GSH
content
Decrease collagen secretion 
and IL-6, IL-8 and TNF-α 
secretion
[69]
Carvedilol Male Wistar rats with ethanol 
(%) fed
10 mg/kg per day for last 7 d of 
total 49 d
Reduced hepatic TG level 
and the accumulation of fatty 
droplets within hepatocytes; 
Down-regulated FAS and 
SREBP-1, and up-regulated 
PPAR-α;
[6]
Inhibited ethanol-induced the 
thickening of zone 3 vessel 
walls
Reduced the activation of 
hepatic stellate cells (HSCs) 
with decrease induction of 
TGF-β1 and collagen
Propylthiouracil Male Sprague-Dawley rat with 
ethanol consumption (36%)
0 mg/kg per day of Wy-14643 
for last 2 wk for the last  d of 4-6 
wk diets with alcohol
Increased hepatic blood flow; 
Reduces oxidative stress
[71]
Colchicine RCT in 74 patients with 
cirrhosis
1 mg/d for 4.4 yr Reduced serum N-terminal 
peptide of type Ⅲ procollagen 
levels
[70]
AH: Alcoholic hepatitis; AMPK: ’ adenosine monophosphate-activated protein kinase; ALT: Alanine transaminase; AST: Aspartate aminotransferase; 
bw: Body weight; COX-2: Cyclooxygenase-2, FA: Fatty acid; FAS: Fatty acid synthase; GSH: Glutathione; HepG2: Hepatoma G2 cell-line; HO-1: Heme 
oxygenase-1; HSC: Hepatic stellate cells; IL-6: Interleukin 6; IL-8: Interleukin-8; LPS: Lipopolysaccharide; mRNA: Messenger ribonucleic acid; P13K: 
Phosphoinositide 3-kinase; PAI-1: Plasminogen activator inhibiter-1; PPAR-α: Peroxisome proliferator-activated receptor-α; RCT: Randomized controlled 
trial; RMT: Respiratory muscle training; SIRT1: Sirtuin 1; SREBP1: Sterol regulator element binding protein 1; TG: Triglycerides; TGF-β: Tissue growth 
factor-β; TNF: Tumour necrosis factor; TNF-α: Tumour necrosis factor-α.
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significant difference between SAM and placebo in liver 
biopsies[51] and no improvement to liver histopathology 
scores or steatosis, inflammation, fibrosis in ALD 
patients[52]. Large and high-quality clinical trials are 
needed to further prove clinical benefits of SAM in ALD. 
Peroxisome proliferator-activated receptor-alpha 
(PPAR-α), a member of the nuclear receptor superfamily 
and mainly expressed in liver, participates in the 
regulation of the transcription of genes involved in fatty 
acid (FA) oxidation, FA transportation, and export of 
free fatty acid. Alcohol intake inhibits FA oxidation via 
the suppression of PPAR-α in hepatocytes[53]. PPAR-α 
agonists, are therefore a potential therapy to reverse 
fat accumulation in AFLD. Many PPAR-α agonists have 
been assessed as a therapeutic approach to patients 
with ALD owing their positive efficacies to their anti-
inflammatory and hypolipidaemic effects, as well as the 
induction of FA oxidation. Adiponectin and its receptors, 
recently, are a new prospective target to manage ALD 
through PPAR-α, TNF-α and sirtuin 1 (SIRT-1)-related 
pathways[54]. Thereby, drug discovery of adiponectin 
agonists may be a potential strategy to manage 
ALD. PPAR-α plays a pivotal role in the regulation of 
adiponectin level and rosiglitazone, one of the PPAR-α, 
agonists has shown to increase the circulating level of 
adiponectin and enhance hepatic adiponectin receptors 
(AdipoRs) in ethanol-fed mice[55]. These increments 
are correlated with the activation of the SIRT-1-AMPK 
signalling system. Carvedilol, a beta-blocker, has 
been recently reported to attenuate the development 
of AH by decreasing hepatic trigylceride (TG) levels 
and lipid droplets within hepatocytes through down-
regulation of fatty acid synthase (FAS) and sterol 
regulator element binding protein 1 (SREBP-1), and 
up-regulated PPAR-α[56]. Carvedilol also prevented 
ethanol-induced thickening of zone 3 vessel walls and 
reduced HSC activation, decreased induction of TGF-β1 
and collagen[56]. Metformin, an antidiabetic drug, has 
recently been discovered to improve HS by lowering 
fat accumulation and liver damage in mouse models of 
acute and chronic alcohol stimulation. This was through 
the prevention of the up-regulation of plasminogen 
activator inhibitor-1 and improvement of insulin 
resistance and liver injury by increasing PPAR-γ and 
adiponectin levels[57,58].
Although CYP2E1 inhibitors prevent alcohol-induced 
liver damage, compounds, which have been available 
in commercial markets, have been too toxic for clinical 
use. Polyenylphosphatidylcholine (PPC), an innocuous 
mixture of polyunsaturated lecithins, extracted from 
soybeans, was recently showed to reduce CYP2E1 
activity and also attenuate hepatic oxidative stress 
and fibrosis[59]. However, one randomized controlled 
trial (RCT) did not confirm the clear association with 
the progression of liver fibrosis[60]. Further studies 
into the effect of PPC on ALD should be encouraged. 
Clomethiazole, another potential CYP2E1 inhibitor, has 
also shown to protect the liver from injury in ethanol-
fed rats and humans[61,62].
The liver and GI tract shares a reciprocal relationship 
and therefore establishing healthy gut microbiota has 
been put forward as a strategy in the treatment of 
ALD. Lipopolysaccharide (LPS) binds to CD14 in Kupffer 
cells which reacts with toll like receptor-4 (TLR-4) 
to activate and release pro-inflammatory cytokines 
genes[63]. LPS signaling and gut microbiota can be 
adjusted by probiotics, prebiotics and TLR-4 antagonists 
to treat ALD[64]. In animal experiments, treating with 
antibiotics or lactobacillius improved ALD by reducing 
the gut microflora which suggests that gut-derived 
endotoxin/LPS may be important in the study of ALD[65]. 
The modified probiotic, Escherichia coli Nissle 1917 
was shown to secrete pyrroloquinoline quinone (PQQ), 
which decreased lipid peroxidation and increased GSH 
to have an anti-inflammatory, anti-oxidant and anti-
hyperlipidaemia effect in acute alcohol exposure in 
rats[66]. LPS antibody may also benefit injury from LPS 
induced by exposure to microorganisms in the gut. 
The outcome of experimental studies has provoked the 
need to compare the effects of LPS antibodies when 
combined with corticosteroids for translation into clinical 
trials for AH[67].
As mentioned, oxidative stress is regarded as a 
key player in the pathogenesis of ALD with increasing 
evidence of its importance, such as products of lipid 
peroxidation being detected in both heavy drinkers 
and ALD patients[68]. It, therefore, has been anticipated 
that anti-oxidant therapy would benefit the outcomes 
for ALD patients. In an animal study, metadoxine had 
preventative effects of lipid peroxidation and GSH 
depletion in human hepatocyte (HepG2), exposed with 
ethanol and acetaldehyde[68]. In HSC, metadoxin also 
prevents the increase of collagen production and TNF-α 
secretion[69].
In addition, some drugs have been used for alcoholic 
liver cirrhosis or fibrosis. Colchicine when administered 
(1 mg/d) to patients with chronic liver cirrhosis over 
a three year period displayed anti-fibrotic effects[70]. 
Propylthiouracil (PTU), typically used as an anti-thyroid 
medication may also ameliorate liver fibrosis. PTU has 
been suggested as a therapeutic drug to treat alcohol-
induced liver cirrhosis as it increases hepatic blood flow 
and also reduces oxidative stress in rats[71].
Approach to late stage ALD
Liver transplantation is an effective therapy and is 
the next viable option for ALD patients with alcoholic 
cirrhosis who have not responded to abstaining from 
alcohol. Liver transplantation proposes to be a rescue 
option for patients with decompensated liver injury 
and no response from pharmaceutical therapy[72]. 
Liver transplantation is regarded as a final treatment 
option for end-stage ALD. However, many reviews 
have reported that relapse incidences following 
liver transplantation are common and generally 
occurs in approximately 10%-52%[73,74] of patients. 
Moreover, patients who have been treated with liver 
transplantation related to ALD display an increased 
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likelihood of de novo cancer in other organs, especially, 
a high rate of cardiovascular complications[75-77]. In 
addition, the transplantation should be followed after six 
months of abstinence to avoid histological damage[78,79].
Safety issues with drug treatment
Chronic alcohol uses and subsequent injury to the liver 
involves various changes to cells and molecules that 
can compromise the metabolic capabilities of the liver. 
Therefore, medications that rely mainly on the liver 
for their metabolism and clearance should be used 
with caution as there is subsequently less elimination 
and higher plasma concentrations[80]. Impaired drug 
metabolism may also relate to changes of the enzyme, 
CYP2E1[81] which is effected by chronic alcohol use. 
Additionally, in a cirrhotic liver, drug administration may 
also be compromised with an increased risk for adverse 
drug reactions. Furthermore, adverse reactions in the 
treatment of ALD may often occur due to individual 
differences such as food intake, genetic differences, 
age, gender and environmental factors including 
obesity and diabetes. Although it was found that there 
was no significantly increased risk of hepatotoxicity 
in patients with liver disease[80], there still should be 
considerable attention to dosage when medicating 
ALD patients to minimise the risk of adverse drug 
reactions and hepatotoxicity. Caution, for example, 
should also be taken when using corticosteroids and 
anti-TNF medications[82] in the hospital setting due to 
an increased risk of immune-related events including 
pneumonia, staphylococcus septicaemia, candida 
septicaemia and GI bleeding[83]. This outcome was seen 
in a previous study investigating the effects of infliximab 
and prednisolone which was terminated prematurely 
due to a significantly higher occurrence of severe 
infections in the treatment group when compared 
to placebo and prednisolone[83]. Corticosteroids also 
increase the risk of coincidental bacterial infections, 
gastrointestinal bleeding, or renal failure indicating 
the need for more clinical evidence to confirm this 
safety issue. Metformin and alcohol combination may 
produce severe consequences as a side effect of lactic 
acidosis. This condition can generate when the blood 
has insufficient oxygen, which is required to transport 
the glucose throughout the body. Metformin also should 
be prudent in patients with cirrhosis due to arterial 
hypoxemia[84]. Other drugs lack evidence in human 
models beyond preliminary trials due to toxicity or 
no significant treatment effect. This could perhaps be 
influenced by the high morbidity rates and short-term 
mortality associated with end stage ALD, especially 
acute AH. This highlights the need for complementary 
and alternative medicine (CAM) where side effects and 
potential for toxicity are significantly reduced.
Natural medicines as a potential alternative treatment of 
ALD
CAM encompasses a wide range of approaches with 
many advantages as it is readily available, has fewer side 
effects and is a natural way of healing with lasting effects 
when compared to conventional medicines[85]. With 
these benefits, natural therapy and herbal medicines 
have attracted a lot of attention as a potential therapy 
for the treatment of ALD. It was found that 41% of 
outpatients with liver disease had utilized some form 
of CAM[86]. In the US survey, Silymarin and garlic were 
reported as the most used herbs for liver disease with 
12% and 8% respectively. Ginseng (6%), green tea 
(5%), gingko (5%), echinacea (5%), and St. John’s wort 
(4%) have also been reported. Other than silymarin, the 
only herb used specifically for liver diseases was licorice 
root (1%)[87]. Herbal medicines and formulations are 
commonly grouped according to country. This includes 
Traditional Chinese Medicine (TCM), Japanese Herbal 
Medicine, Ayurvedic Medicine (Indian Subcontinent), 
Traditional African Medicine, Traditional Medicines of 
the Amazonian Basin in South America, and Arab 
Traditional Medicine. In general, the markers to display 
the benefits of herbal products rely on serum/plasma 
enzymes such as alanine transaminase (ALT), aspartate 
aminotransferase (AST) and alkaline phosphatase (ALP). 
Other characteristics, including lipid lowering effects, 
anti-oxidant, anti- inflammation and anti-fibrotic effects 
are also used to show the hepatoprotective effects[87]. 
This review may describe the potential role and effects 
of natural products in chronic ALD including biological 
properties and their beneficial effects. A summary list of 
natural compounds is shown in Table 2.
Green tea polyphenols
Green tea is derived from the leaves and buds of 
Camellia sinensis. Green tea contains rich polyphenolic 
compounds and has pleiotropic effects including anti-
oxidant, hypolipidaemic and anti-inflammatory actions. 
Green tea polyphenols (GTP) significantly ameliorated 
ethanol-induced hepatic necrosis. Furthermore, while 
ethanol significantly increased the accumulation of 4- 
hydroxynonenal, a product of lipid peroxidation and 
an index of oxidative stress, green tea extract down 
regulated this effect. This indicated that GTP protects 
alcohol-induced liver injury through preventing oxidative 
stress[88]. The major tea catechins include epicatechin 
(EC), epicatechin gallate (ECG), epigallocatechin 
(EGC), and epigallocatechin gallate (EGCG) with 
EGCG being the major constituent of the catechins 
with numerous biological functions[89-91]. Our previous 
study showed total GTP and EGCG enhance glycogen 
synthesis and inhibit lipogenesis in hepatocytes[92]. 
EGCG treatment also significantly decreased elevated 
serum ALT in alcohol-induced rats[88] and normalised 
the activities of enzymatic anti- oxidants[93]. Another 
study has reported that EGCG ameliorated plasma 
endotoxin levels in alcohol-induced female rats with 
endotoxemia, displaying anti- inflammatory effects 
through the inhibition of TNF-α, COX-2, and iNOS 
mRNA expression[94]. EGCG also protected against liver 
impairment through the enhancement of FA oxidation 
with increased carnitine palmitoyl transferase 1 (CPT-1) 
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Table 2  The information of effects of current natural medicines on the treatment of alcoholic liver disease
Medicine/
compound 
Type of model Dosage/duration Effects Mechanisms Ref.
Vitamin E and C Malnourished rats with 
ethanol
Vitamin E (1 mg/kg) 
Vitamin C (10 mg/kg); single 
and combined treatments
Decreased ethanol induced 
hepatic glutathione peroxidase 
activity and hepatic fibrosis; 
Attenuated the development 





Male albino Wistar rats with 
Ethanol (6 g/kg per day) for 
60 d
EGCG (100 mg/kg per day) 
for the last of 30 d of ethanol 
administration
Normalization of activities of 
enzymatic antioxidants;
Reduction of lipid peroxidation
[93] 
Female Sprague-Dawley rats 
with ethanol (6%)
EGCG (100 mg/bw) Partly blocked the gut leakiness; 
Reduced endotoxemia and lipid 
peroxidation
Blunted the elevated 
expressions of CD14, TNF-α, 
COX-2 and iNOS
[94] 
Male Wistar rats with ethanol 
for  wk
EGCG contained diet (3 g/L) 
for 2 wk and then ethanol-
EGCG diet for  wk
Reduced serum AST and ALT Enhancement of FA oxidation 






RCT, double-blind, 170 
patients with cirrhosis
140 mg/d for 3 times orally Reduced the rate of mortality 
No side effect
[33]
Alcohol induced baboons 
(0% of calories)
0.84 mg/calorie for 36 mo Improve histologic stage of 
fibrosis
Decrease collagen I and (I) 
procollagen
[100]
Alcohol and high fat induced 
rats
100 mg/kg per day, 10 mg/
kg per day, 200 mg/kg per 
day for 6 wk
200 mg/kg per day decrease 
serum ALT and AST and 
hepatic fat contents
Attenuated NF-κB p6, 
ICAM-1 and IL-6 were found 
in silymarin groups (10 mg/
kg, 200 mg)
[101]
 Betaine Ethanol diet Wistar rats 1% (w/v) in diet Decrease hepatic ballooning and 
fat contents
Attenuate NOS production; 
Decrease CYP2E1 protein and 
activity
[106]
High fat containing ethanol 
diet rats 6 g/kg for 8 more wk
200 and 400 mg/kg per day 
for 4 wk
Decrease ALT and AST Inhibition of TLR-4 
expression;
Decrease serum endotoxin, 





Ethanol-CCl4 induced male 
SD rats
Intraperitoneal injections of 
potenlin (acquired from Hai 
Ning Pharmaceutical Co., Zhe 
Jiang, China)
Decreasing serum ALT levels Normalized NF-κB binding 
activity
[114]
Gisenosides Ethanol-feeding mice Ethanol 
feeding hepatocytes (AML12 
cell lines)
Red ginseng extract containing 
abundant ginsenosides (Rb1, 
Rb2, and Rd) (20 mg/kg or 




Decreases in hepatic triglyceride 
content




P40 2E1, 4-hydroxynonenal, 
and nitrotyrosine levels; 
Activation of AMPK-SIRT1
[166]
Alcohol consumption with 
high fat diet mice
Red ginseng (200 mg/kg per 
day) for last 2 wk
Lower ALT levels and no 
different AST
Reduced level of TNF-α and 




EtOH (30 mM) induced Chang 
liver cells
20, 40, 60 mg/mL Increased GSH/GSSG ratio 
Reduced EtOH-induced LDH 
leakage
Inhibition of NF-κB [129]
Ethanol induced rats (6 g/kg 
per day) for 30 d
200 mg/kg per day for 30 d Improved lipid profile and 
reduced collagen content, 
crosslinking, aldehyde content 
and peroxidation
[132]
Curcumin Alcohol (100 mM) induced rat 
primary hepatocytes





400 mg/kg bw Improved liver pathology, 
decreasing elevation of hepatic 
MDA
Suppressing of NF-κB 
activation
[134]
LIV-2 Ethanol-induced HepG2 cells 
(100 and 200 mM )
1% or 2% Liv.2 for 24 h Normalized suppressed 
PPAR-α and induced TNF-α
[148]
ACC: Acetyl-CoA carboxylase; AML12: Alpha mouse liver 12; AMPK: ’ adenosine monophosphate-activated protein kinase; ALT: Alanine transaminase; 
AST: Aspartate aminotransferase; bw: Body weight; CCL4: Chemokine ligand 4; CD14: Cluster of differentiation 14 gene; COX-2: Cyclooxygenase-2; CPT-1: 
Carnitine palmitoyl-transferase 1; CYP2E1: Cytochrome P40 2E1; EGCG: Epigallocatechin-3-gallate; etOH: Ethanol; FA: Fatty acid; GSH: Glutathione; 
GSSG: Glutathione disulfide; HepG2: Hepatoma G2 cell-line; HO-1: Heme oxygenase-1; ICAM-1: Intercellular adhesion molecule-1; IFN-γ: Interferon-γ; 
IL-1: Interleukin 1; IL-6: Interleukin 6; IL-10: Interleukin-10; IL-18: Interleukin-18; iNOS: Inducible nitric oxide synthase; LDH: Lactate dehydrogenase; 
MDA: Malondialdehyde; NF-κB: Nuclear factor kappa; NOS: Inducible nitric oxide synthase; RCT: Randomized controlled trial; SIRT1: Sirtuin-1; TLR-4: 
Toll-like receptor-4; TNF-α: Tumour necrosis factor-α.
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levels[95]. Despite much evidence supporting the effects 
of EGCG on ALD, clinical studies are still limited and 
large-scale human studies may be needed to confirm 
this effect. GTP, catechins may also increase HO-1 
activity to reduce oxidative stress in human liver tissue 
(hHeps). Administering polyphenols prior to ethanol 
exposure reduced the diminishing of GSH to display a 
protective effect on liver cells by regulating the immune 
system and pro-inflammatory mediators such as 
TGF-β1[96].
Herbal medicines
Silymarin (Milk thistle), which is one of the active 
compounds extracted from Silybum marianum 
(Asteraceae) is the most common type of CAM therapy 
for treatment of liver diseases[85]. Silymarin is a 
complex mixture of polyphenolic molecules including 7 
flavonolignans (silybinA, B, isosilybin A, B, silychristin, 
isosilychristin, silydianin) and 1 flavonoid (taxifolin)[97]. 
Silibinin, which is a semi-purified fraction of silymarin, 
has been shown to be a radical scavenger[98] and a RCT 
with silymarin also improved survival from patients 
with alcoholic and non-alcoholic cirrhosis without any 
side effect[33]. Another RCT was also conducted with 
the prospective effect of silymarin (140 mg/d) in AH[99]. 
Mechanisms by which silymarin extracts ameliorate 
liver disease include anti- inflammatory, anti-oxidative, 
antifibrotic, and immune-modulating activities[100]. 
Silymarin has retarded the development of alcohol-
induced hepatic fibrosis in baboons by preventing 
collagen type Ⅰ and decreasing histological progression 
to fibrosis[100]. Silymarin also reduces the elevated 
serum AST and ALT levels, and decreases hepatic lipid 
contents in alcohol-induced fatty liver in rats. These 
effects may be through down-regulating the expression 
of NF-κB p65, ICAM-1 and IL-6 in liver tissue[101]. 
However, Cochrane Database reviews have been un-
successful in demonstrating the beneficial effect of 
silymarin on ALD. Further studies are needed to provide 
the appropriate data concerning efficacy.
Betaine is another natural dietary compound, 
synthesized in vivo from choline and converts homo-
cysteine to methionine[102]. Betaine (trimethylglycine), 
a pivotal nutrient for humans, can be acquired from a 
wide range of foods and nutritional supplements[103]. 
It attenuates AH by restoring phosphatidylcholine 
generation via the phosphatidylethanolamine methy-
ltransferase pathway[104]. Betaine also increases 
SAM, normalizing hepatocellular SAM:S-adenosyl-L-
homocysteine ratio[105], resulting in the attenuation of 
fatty liver[103]. The study of mitochondrial dysfunction 
in the progression of ALD has also been enforced by 
many research areas. Betaine gives a beneficial effect 
against loss of oxidative phosphorylation system 
proteins by alcohol, by preventing NOS2 induction 
and NO generation in male Wister rats with exposed 
to ethanol[106]. The mechanism of betaine in liver is 
also involved in the suppression of endotoxin/TLR-4 
signaling pathways. Betaine treatment decreased the 
levels of serum ALT, AST, endotoxin, TNF-α, IFN-γ, 
IL-18, and TLR-4, and improved the degree of HS and 
inflammation in liver tissues in rats with alcohol-induced 
liver injury[107].
Glycyrrhiza glabra (Leguminosae), commonly named 
licorice root, is a perennial herb cultivated in temperate 
and subtropical regions of the world as well as central 
and South-Western Asia[108]. Glycyrrhizin, as a main 
constituent in aqueous extract, is a conjugate of two 
molecules of glucuronic acid and one of 18β-glycyrrhetic 
acid[109]. Glycyrrhizin is hydrolysed by intestinal bacterial 
into 18β-glycyrrhetic acid, which is reabsorbed into 
the bloodstream. Glycyrrhizin suppressed serum AST 
and ALT levels and histologically inhibited the spread of 
deteriorating areas in hepatocytes in an animal model 
of concanavalin A-induced liver injury[110]. Moreover, the 
effects of Glycyrrhizin has extended to the attenuation 
of inflammation response by regulation of NF-κB and 
MAPK pathway[111] and inhibition of TNF-α, ROS, and 
proinflammatory interleukins such as IL-6 and IL-
1β[112,113]. Another beneficial effect of glycyrrhizin, from 
Potenlini compound, was shown in ethanol-CCl4 induced 
liver cirrhosis rats by decreasing serum ALT levels and 
normalising NF-κB binding activity[114,115]. In clinical 
trials, glycyrrhizin is mostly used to treat hepatitis C 
and interferon treatment[16]. One clinical trial showed 
to lower level of ALT with 200 mg of glycyrrhizin for 5 
d per week for approximately 10 years in hepatitis C 
patients[116]. Glycyrrhizin has potential effects to cure 
various chronic liver diseases but large-scale, rigorously 
designed clinical trials for ALD is warranted.
Ginseng, an ancient medicinal herb, has been 
popular as a tonic for the treatment of various dis-
eases including diabetes and hepatic diseases[117]. 
Ginsenosides, the main active constituent groups of all 
ginseng species, has been used as a supplementary 
medicine and is mostly responsible for the beneficial 
pharmacological effects in metabolic disorders and 
various cancer via its ability to boost immunity and its 
anti- inflammation function[118,119]. Ginsenoside Rb1, 
as the most abundant ginsenoside in P. ginseng has 
improved hepatic fibrosis induced by CCl4 by down 
regulation of hepatic prostaglandin E2 and TIMP-1[120]. 
Ginsenoisde Rg1 showed to inhibit TNF-α-mediated 
NF-κB transcriptional activity in HepG2 cells with IC50 
of 28.14 µmol/L and gene expression of iNOS and 
COX-2 inducible inflammatory enzymes[121]. It was also 
reported that ginsenoisde Rc (40 mg/kg) attenuates 
AFLD in alcoholic-fed ICR mice through the regulation 
of AMPK and MAPK pathways[122]. Red ginsengs, which 
contain an abundance of ginsenosides, showed to 
improve chronic alcohol-induced histopathological 
changes and hepatic TG content through inhibition of 
the lipogenesis pathway and AMPK-SIRT1 activation in 
alcohol-fed mice[123]. Red ginseng also reduced levels 
of TNF-α and IL-1β which were increased by alcohol 
consumption with a high fat diet in mice[124]. Recently, 
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compound K which is a metabolite form of ginsenoside 
Rb1 and Rc has been identified as an inducer to increase 
AMPK expression, resulting in reduction of lipid droplets 
and hepatic TG accumulation in high FA exposed human 
hepatocytes (Huh7). This compound had better efficacy 
to treat HS compared to metformin[125]. With the 
hepatoprotective effects of many types of ginsenosides, 
these herbal components should be potential targets to 
improve liver damage caused by alcohol abuse.
Fenugreek (Trigonella foenum graecum) seeds 
have been reported to have beneficial effects on 
enhancing the antioxidant apparatus[126]. Fenugreek 
seeds also have been used in remedies for diabetes 
and high cholesterol in various traditional medicines 
and proven experimentally in diabetic humans[127]. The 
polyphenolic extract of the seeds is the main constituent 
beneficial for the treatment of ALD according to many 
articles. In general, fenugreek seed polyphenols 
contain five different polyphenolic flavonoids, vitexin, 
tricin, naringenin, quercetin, and tricin-7-O-b-D-
glucopyranoside[128]. These polyphenols prevent the 
alcohol-induced toxic effect in human Chang liver 
cells through improvement of GSH/GSSG ratio[129]. 
Interestingly, quercetin ameliorated ethanol-stimulated 
mitochondrial dysfunction by induced permeability 
transition though suppressing GSH depletion. This 
indicates a promising preventive strategy for ALD[130,131]. 
Fenugreek seed polyphenols also have demonstrated 
improvement to lipid profiles and collagen content 
in alcohol-fed rats[132]. Compared to other herbal 
medicines, however, the clinical studies of fenugreek 
seed polyphenols are lacking evidence in metabolic 
disorders, especially in relation to ALD, suggesting the 
need for accurate standardization of polyphenols and 
their individual efficacy for the treatment of ALD.
Curcumin, commonly called turmeric yellow and 
compound of curcuma longa, is a low-molecular weight 
polyphenol derived agent. It is commonly used in 
Ayurvedic medicine and has various pharmacological 
effects including anti-oxidative, anti- inflammatory, 
and hepatoprotective activities[105]. This historical 
use of curcumin has prompted investigation into the 
hepatoprotective effects against liver damage induced 
by alcohol abuse and the molecular mechanisms, 
however the research in this area is still lacking. 
Curcumin has ameliorated malondialdehyde (MDA) 
and AST and improved GSH and heme oxygenase-1 
(HO-1) induction in alcohol (100 mM) induced rat 
primary hepatocytes[133]. Curcumin (400 mg/kg bw) 
has also been examined in alcohol-induced female 
Sprague-Dawley rats to show improvement by reducing 
the elevation of hepatic MDA, and the suppressing of 
NF-κB activation[134]. Another similar result confirmed 
the inhibition of the expression of NF-κB-dependent 
genes by the supplementation of curcumin (75 mg/kg 
per day) for 4 wk in rats[135]. Recently, low dosage of 
curcumin prevented HS compared with the alcohol 
control group with inhibition of dehydrogenase, ALDH2 
as well as CYP2E1 activation[136]. Curcumin also proved 
its anti-oxidant effect against ethanol-exposed mice by 
decreasing ROS generation[137]. Despite the beneficial 
effects of curcumin in ALD, it is unfavourable to apply as 
a medical strategy due to its decreased bioavailability 
and rapid metabolism with systemic elimination in 
animals and humans, suggesting an investigation of 
more sophisticated pharmacokinetic improvements of 
curcumin such as curcumin phospholipid complex or 
curcumin nanoparticles[105,138].
Herbal formulas to treat ALD
Historically, some herbal blends have been commonly 
used for hepatic disorders around the world. Clinical 
trials to evaluate their efficacy are, however, challenging 
to demonstrate due to heterogeneous formulations 
and dosages. Moreover, these blends have not been 
regulated by the Food and Drug Administration. 
In this review, a few blends are evaluated in ALD. 
Herbal Medicine861 (HM 861) consists of 10 herbs, 
based on TCM including Salvia miltiorrhiza, Astragalus 
membranaceus and Spatholobus suberectus[139]. 
HM861 has shown the inhibition of HSC proliferation 
and induction of HSC apoptosis in patients with chronic 
hepatitis[140].
Moreover, the compound also suppressed tissue 
inhibitor metalloprotease 1 (TIMP-1) mRNA expression 
in HSC-T6 cells[141]. In clinical trials, this herbal blend 
was tested for anti-fibrotic activity encompassing 107 
patients with hepatitis B resulting in the drop of ALT 
levels to the normal range in 73% of patients[142]. In 
a clinical trial, HM861 showed to improved fibrosis 
and early cirrhosis in 52 patients with HBV-related 
fibrotic patients with the hepatic inflammatory scores 
also decreased[143]. More Cochrane reviews, however, 
are needed to confirm the efficacy of the blend in the 
treatment of ALD. TJ-9, also referred to as Sho-saiko-
to in Japan or xiao-chai-hu- tang in China, containing 7 
herbal constituents including: bupleurum root, pinellia 
tuber, scutellaria toot, jujube fruit, ginger rhizome, 
ginseng root, and glycyrrhiza root. The formula has 
been traditionally used for the treatment of liver 
diseases. Usually, the preparation contains 7.5 g of 
TJ-9 with the active components, baicalin and baicalein, 
responsible for the anti-oxidant activity[144]. Although the 
exact of mechanism of TJ-9 is unknown, one anticipated 
mechanism may be exposed in the observation 
of stellate cells which has shown an inhibition of 
α-smooth muscle actin, type I collagen production, 
and cell spreading, indicating the suppression of HSC 
activation[144]. TJ-9 has been associated with several 
cases of interstitial pneumonitis, especially when used 
with interferon for the treatment of chronic hepatitis[145]. 
Liv-52, which is an Indian Ayurvedic medicine that 
has been used for the treatment of liver diseases, is a 
herbal preparation including Capparis spinosa (Himsara), 
Cichorium intybus (Kasani), Mandur bhasma, Solanum 
nigrum (Kakamachi), Terminalia arjuna (Arjuna), 
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Cassia occidentalis (Kasamarda), Achillea millefolium 
(Biranjasipha), and Tamarix gallica (Jhavaka)[146]. It 
was originally used to treat ALD, but a recent RCT 
from Europe demonstrated a detrimental effect on 
advanced alcohol-induced cirrhosis[147]. Contrastingly, 
an in vitro study, reported that Liv.52 improved PPAR-γ 
suppression and TNF-α expression in HepG2 cells[148]. 
Another clinical study also showed the efficacy of LIV.52 
in 26 cirrhotic patients for 6 mo with normalized serum 
ALT and AST levels compared to the placebo group[149]. 
Although there are many positive effects of LIV.52 
for the improvement of ALD, underlying molecular 
mechanisms are still necessary to support its potential 
function. In summary, many compounds are available 
on the open market to treat ALD, but their efficacy data 
is still not supported by clinical trials. Comprehension 
of herbal interaction with pharmacological medicines is 
also necessary to improve the treatment of ALD.
The combination therapies of drugs and natural agents
More readily available on the market and popular 
than ever, CAM and herbal therapy are increasingly 
attractive treatments for chronic liver diseases 
with many advantages, such as low side effect and 
toxicity. Augmentation of herb-drug interaction has 
consequently followed stipulating dialogue between 
pharmaceutical experts and practician. Although 
there is strong evidence, supporting the use of herbal 
medicine for the treatment of ALD, combination therapy 
should be speculated for any safety issues. Magnesium 
isoglycyrrhizinate injection is one example of a drug 
containing glycyrrhizin and possesses effective and 
safe treatment for chronic liver diseases[150] and down 
regulates the progress of pulmonary fibrosis[151]. 
Glycyrrhizin also has been combined with matrine to 
improve CCL4-induced liver fibrosis through lowering 
levels of collagen and less HSC proliferation[152], 
suggesting the positive effect of their combination to 
protect against liver fibrosis. Recently, a combination 
of silymarin and SAM was evaluated in ALD markets 
with much promise[153]. There have been some cases 
of adverse events and hepatotoxicity caused by herbal 
medicines[154]. Xiao Chaihu Tang, alone or in combination 
with interferon, may induce acute interstitial pneumonia 
in chronic hepatitis patients[155]. Despite the emerging 
of CAM on the markets, documented herb-drug 
interactions are still sparse, especially in relation to 
ALD with a reliance only on individual case reports. 
Although some combinations of CAMs and conventional 
drugs contribute many beneficial efficacies, some herb-
drug interaction also may be associated with toxicity in 
certain situations such as the combination of silymarin 
with indinavir therapy in AIDS patients[156].
FUTURE OUTLOOK AND PERSPECTIVE
It is undeniable that chronic alcohol abuse leads to 
deleterious implications for the liver regardless of age, 
gender or other factors. The more advanced the stage 
of alcoholic liver disease, the more morbid and life-
threatening the complications become. Various therapies 
should, therefore, aim to reverse these complications 
but are often only palliative. As an initial therapy of ALD, 
abstinence from alcohol accompanied with basic lifestyle 
modifications when appropriate. When the injury 
becomes decompensated, pharmacological therapy 
should be accompanied to reverse the more severe 
stages of ALD. The present studies are still inconclusive 
with humble methodological quality and design, high 
heterogeneous patient populations, and poorly defined 
point of progression of ALD. These flaws may partly 
explain the conflicting reports in the literature to 
support the effectiveness of treatment for ALD for many 
conventional medications, such as Corticosteroids, PTX, 
and SAM. Mechanistic studies are still insufficient to 
prove their pharmaceutical potency and future studies 
will be thirsty to investigate the molecular mechanisms 
related in the complex relationships between ethanol 
metabolism, oxidative stress, immune response, HSC 
activation and extracellular matrix (ECM) remodelling. 
Larger RCTs with a longer follow-up period are required 
for further evaluation.
Increasing attention has been paid to herbal 
medicines as a newly emerging treatment strategy for 
ALD. In this review, we summarized functionalities of 
CAM for the prevention and treatment of ALD. Most 
single herbs and formulae have resulted in improvement 
of ALD -related conditions with multiple and diverse 
mechanisms of actions in spite of their mild side effects. 
To date, only a few active compounds from herbal 
extracts have been identified as candidates to treat 
ALD and alcohol induced liver injury. Although many 
herbal constituents have shown promising potential for 
the treatment of ALD with multi-targets, the underlying 
molecular mechanisms, especially that of single herbal 
compounds, have not been completely elucidated. 
Moreover, clinical trials to adjust concurrent systematic 
review are still required in the area of ALD research. 
More profound studies underlying the prospective effect 
of herbal medicines should be further investigated. In 
addition, some unique therapies are now increasing to 
develop the treatment of ALD. Epigenetic regulation 
underlying alcohol metabolism, such as histone 
modification may be a new trend to advance effective 
treatment strategies for ALD[157]. Acetate may affect 
histone modification by up-regulating acetyl-CoA 
and enhance the inflammation in ethanol-exposed 
macrophages by interfering histone deacetylase 
activity[158]. With many natural products potentially 
possessing this ability of epigenetic modification, it 
would be a particularly beneficial breakthrough for ALD 
patients.
REFERENCES
1 Marra F, Efsen E, Romanelli RG, Caligiuri A, Pastacaldi S, 
Batignani G, Bonacchi A, Caporale R, Laffi G, Pinzani M, Gentilini 
12 January 7, 2016|Volume 22|Issue 1|WJG|www.wjgnet.com
P. Ligands of peroxisome proliferator-activated receptor gamma 
modulate profibrogenic and proinflammatory actions in hepatic 
stellate cells. Gastroenterology 2000; 119: 466-478 [PMID: 
10930382]
2 European Association for the Study of Liver. EASL clinical 
practical guidelines: management of alcoholic liver disease. J 
Hepatol 2012; 57: 399-420 [PMID: 22633836 DOI: 10.1016/
j.jhep.2012.04.004]
3 Morgan TR, Mandayam S, Jamal MM. Alcohol and hepatocellular 
carcinoma. Gastroenterology 2004; 127: S87-S96 [PMID: 
15508108]
4 Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular 
carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 
2004; 127: S35-S50 [PMID: 15508101]
5 Rehm J, Samokhvalov AV, Shield KD. Global burden of alcoholic 
liver diseases. J Hepatol 2013; 59: 160-168 [PMID: 23511777 DOI: 
10.1016/j.jhep.2013.03.007]
6 World Health Organization. Global status report on alcohol 
and health 2011. Available from: URL: http://www.who.
int/substance_abuse/publications/global_alcohol_report/
msbgsruprofiles.pdf
7 Everitt H, Hu M, Ajmo JM, Rogers CQ, Liang X, Zhang R, Yin H, 
Choi A, Bennett ES, You M. Ethanol administration exacerbates the 
abnormalities in hepatic lipid oxidation in genetically obese mice. 
Am J Physiol Gastrointest Liver Physiol 2013; 304: G38-G47 [PMID: 
23139221 DOI: 10.1152/ajpgi.00309.2012]
8 Gao B, Bataller R. Alcoholic liver disease: pathogenesis and new 
therapeutic targets. Gastroenterology 2011; 141: 1572-1585 [PMID: 
21920463 DOI: 10.1053/j.gastro.2011.09.002]
9 Zakhari S, Li TK. Determinants of alcohol use and abuse: Impact of 
quantity and frequency patterns on liver disease. Hepatology 2007; 
46: 2032-2039 [PMID: 18046720 DOI: 10.1002/hep.22010]
10 You M, Crabb DW. Recent advances in alcoholic liver disease II. 
Minireview: molecular mechanisms of alcoholic fatty liver. Am 
J Physiol Gastrointest Liver Physiol 2004; 287: G1-G6 [PMID: 
15194557 DOI: 10.1152/ajpgi.00056.2004]
11 Gao B. Cytokines, STATs and liver disease. Cell Mol Immunol 2005; 
2: 92-100 [PMID: 16191414]
12 Friedman SL. Hepatic stellate cells: protean, multifunctional, and 
enigmatic cells of the liver. Physiol Rev 2008; 88: 125-172 [PMID: 
18195085 DOI: 10.1152/physrev.00013.2007]
13 Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism 
in development progression of liver injury caused by non-alcoholic 
or alcoholic steatohepatitis. J Toxicol Sci 2007; 32: 453-468 [PMID: 
18198478]
14 Enomoto N, Ikejima K, Bradford BU, Rivera CA, Kono H, Goto M, 
Yamashina S, Schemmer P, Kitamura T, Oide H, Takei Y, Hirose M, 
Shimizu H, Miyazaki A, Brenner DA, Sato N, Thurman RG. Role of 
Kupffer cells and gut-derived endotoxins in alcoholic liver injury. J 
Gastroenterol Hepatol 2000; 15 Suppl: D20-D25 [PMID: 10759216]
15 Veldt BJ, Lainé F, Guillygomarc’h A, Lauvin L, Boudjema K, 
Messner M, Brissot P, Deugnier Y, Moirand R. Indication of liver 
transplantation in severe alcoholic liver cirrhosis: quantitative 
evaluation and optimal timing. J Hepatol 2002; 36: 93-98 [PMID: 
11804670]
16 Hanje AJ, Fortune B, Song M, Hill D, McClain C. The use of 
selected nutrition supplements and complementary and alternative 
medicine in liver disease. Nutr Clin Pract 2006; 21: 255-272 [PMID: 
16772543]
17 Luca A, García-Pagán JC, Bosch J, Feu F, Caballería J, 
Groszmann RJ, Rodés J. Effects of ethanol consumption on hepatic 
hemodynamics in patients with alcoholic cirrhosis. Gastroenterology 
1997; 112: 1284-1289 [PMID: 9098014]
18 Kadden R. Cognitive-behavioral Coping Skills Therapy Manual: 
A Clinical Research Guide for Therapists Treating Individuals 
with Alcohol Abuse and Dependence. US: Department of Health 
and Human Services, Public Health Service, National Institutes of 
Health, National Institute on Alcohol Abuse and Alcoholism, 1995
19 Bouza C, Angeles M, Muñoz A, Amate JM. Efficacy and safety of 
naltrexone and acamprosate in the treatment of alcohol dependence: 
a systematic review. Addiction 2004; 99: 811-828 [PMID: 15200577 
DOI: 10.1111/j.1360-0443.2004.00763.x]
20 Williams SH. Medications for treating alcohol dependence. Am Fam 
Physician 2005; 72: 1775-1780 [PMID: 16300039]
21 Garbutt JC ,  West SL, Carey TS, Lohr KN, Crews FT. 
Pharmacological treatment of alcohol dependence: a review of the 
evidence. JAMA 1999; 281: 1318-1325 [PMID: 10208148]
22 Sofair AN, Barry V, Manos MM, Thomas A, Zaman A, Terrault NA, 
Murphy RC, Stabach N, Huie S, Van Ness G, Bell BP, Bialek S. 
The epidemiology and clinical characteristics of patients with newly 
diagnosed alcohol-related liver disease: results from population-
based surveillance. J Clin Gastroenterol 2010; 44: 301-307 [PMID: 
19745759 DOI: 10.1097/MCG.0b013e3181b3f760]
23 Corrao G, Lepore AR, Torchio P, Valenti M, Galatola G, D’
Amicis A, Aricó S, di Orio F. The effect of drinking coffee and 
smoking cigarettes on the risk of cirrhosis associated with alcohol 
consumption. A case-control study. Provincial Group for the Study 
of Chronic Liver Disease. Eur J Epidemiol 1994; 10: 657-664 [PMID: 
7672043]
24 Klatsky AL, Armstrong MA. Alcohol, smoking, coffee, and 
cirrhosis. Am J Epidemiol 1992; 136: 1248-1257 [PMID: 1476147]
25 Naveau S, Giraud V, Borotto E, Aubert A, Capron F, Chaput JC. 
Excess weight risk factor for alcoholic liver disease. Hepatology 
1997; 25: 108-111 [PMID: 8985274 DOI: 10.1002/hep.510250120]
26 Singal AK, Charlton MR. Nutrition in alcoholic liver disease. Clin 
Liver Dis 2012; 16: 805-826 [PMID: 23101983 DOI: 10.1016/
j.cld.2012.08.009]
27 McClain CJ, Barve SS, Barve A, Marsano L. Alcoholic liver disease 
and malnutrition. Alcohol Clin Exp Res 2011; 35: 815-820 [PMID: 
21284673 DOI: 10.1111/j.1530-0277.2010.01405.x]
28 Hirsch S, de la Maza MP, Gattás V, Barrera G, Petermann M, 
Gotteland M, Muñoz C, Lopez M, Bunout D. Nutritional support in 
alcoholic cirrhotic patients improves host defenses. J Am Coll Nutr 
1999; 18: 434-441 [PMID: 10511325]
29 Frazier TH, Stocker AM, Kershner NA, Marsano LS, McClain CJ. 
Treatment of alcoholic liver disease. Therap Adv Gastroenterol 2011; 
4: 63-81 [PMID: 21317995 DOI: 10.1177/1756283X10378925]
30 Kang YJ, Zhou Z. Zinc prevention and treatment of alcoholic liver 
disease. Mol Aspects Med 2005; 26: 391-404 [PMID: 16099027 
DOI: 10.1016/j.mam.2005.07.002]
31 Das I, Burch RE, Hahn HK. Effects of zinc deficiency on ethanol 
metabolism and alcohol and aldehyde dehydrogenase activities. J 
Lab Clin Med 1984; 104: 610-617 [PMID: 6384394]
32 Zhou Z, Wang L, Song Z, Saari JT, McClain CJ, Kang YJ. Zinc 
supplementation prevents alcoholic liver injury in mice through 
attenuation of oxidative stress. Am J Pathol 2005; 166: 1681-1690 
[PMID: 15920153 DOI: 10.1016/s0002-9440(10)62478-9]
33 Ferenci P, Dragosics B, Dittrich H, Frank H, Benda L, Lochs H, 
Meryn S, Base W, Schneider B. Randomized controlled trial of 
silymarin treatment in patients with cirrhosis of the liver. J Hepatol 
1989; 9: 105-113 [PMID: 2671116]
34 Spahr L, Rubbia-Brandt L, Pugin J, Giostra E, Frossard JL, Borisch 
B, Hadengue A. Rapid changes in alcoholic hepatitis histology under 
steroids: correlation with soluble intercellular adhesion molecule-1 
in hepatic venous blood. J Hepatol 2001; 35: 582-589 [PMID: 
11690703 DOI: 10.1016/S0168-8278(01)00190-8]
35 Taïeb J, Mathurin P, Elbim C, Cluzel P, Arce-Vicioso M, Bernard 
B, Opolon P, Gougerot-Pocidalo MA, Poynard T, Chollet-Martin S. 
Blood neutrophil functions and cytokine release in severe alcoholic 
hepatitis: effect of corticosteroids. J Hepatol 2000; 32: 579-586 
[PMID: 10782906 DOI: 10.1016/S0168-8278(00)80219-6]
36 Tome S, Lucey MR. Review article: current management of 
alcoholic liver disease. Aliment Pharmacol Ther 2004; 19: 707-714 
[PMID: 15043511 DOI: 10.1111/j.1365-2036.2004.01881.x]
37 Phillips M, Curtis H, Portmann B, Donaldson N, Bomford A, 
O’Grady J. Antioxidants versus corticosteroids in the treatment 
of severe alcoholic hepatitis--a randomised clinical trial. J 
Hepatol 2006; 44: 784-790 [PMID: 16469404 DOI: 10.1016/
j.jhep.2005.11.039]
38 Ramond MJ, Poynard T, Rueff B, Mathurin P, Théodore C, Chaput 
13 January 7, 2016|Volume 22|Issue 1|WJG|www.wjgnet.com
JC, Benhamou JP. A randomized trial of prednisolone in patients 
with severe alcoholic hepatitis. N Engl J Med 1992; 326: 507-512 
[PMID: 1531090 DOI: 10.1056/nejm199202203260802]
39 Mathurin P, Abdelnour M, Ramond MJ, Carbonell N, Fartoux L, 
Serfaty L, Valla D, Poupon R, Chaput JC, Naveau S. Early change in 
bilirubin levels is an important prognostic factor in severe alcoholic 
hepatitis treated with prednisolone. Hepatology 2003; 38: 1363-1369 
[PMID: 14647046 DOI: 10.1016/j.hep.2003.09.038]
40 Mathurin P, Beuzin F, Louvet A, Carrié-Ganne N, Balian A, 
Trinchet JC, Dalsoglio D, Prevot S, Naveau S. Fibrosis progression 
occurs in a subgroup of heavy drinkers with typical histological 
features. Aliment Pharmacol Ther 2007; 25: 1047-1054 [PMID: 
17439505 DOI: 10.1111/j.1365-2036.2007.03302.x]
41 Lucey MR, Mathurin P, Morgan TR. Alcoholic hepatitis. N Engl 
J Med 2009; 360: 2758-2769 [PMID: 19553649 DOI: 10.1056/
NEJMra0805786]
42 Akriviadis E, Botla R, Briggs W, Han S, Reynolds T, Shakil O. 
Pentoxifylline improves short-term survival in severe acute alcoholic 
hepatitis: a double-blind, placebo-controlled trial. Gastroenterology 
2000; 119: 1637-1648 [PMID: 11113085]
43 De B, Mandal S, Sau D, Mani S, Chatterjee S, Mondal S, 
Bhattacharya K, Sil K, Bhattacharya R. Pentoxifylline Plus 
Prednisolone versus Pentoxifylline Only for Severe Alcoholic 
Hepatitis: A Randomized Controlled Clinical Trial. Ann Med Health 
Sci Res 2014; 4: 810-816 [PMID: 25328799 DOI: 10.4103/2141-92
48.141562]
44 Doherty GM, Jensen JC, Alexander HR, Buresh CM, Norton 
JA. Pentoxifylline suppression of tumor necrosis factor gene 
transcription. Surgery 1991; 110: 192-198 [PMID: 1858029]
45 Parker R, Armstrong MJ, Corbett C, Rowe IA, Houlihan DD. 
Systematic review: pentoxifylline for the treatment of severe 
alcoholic hepatitis. Aliment Pharmacol Ther 2013; 37: 845-854 
[PMID: 23489011 DOI: 10.1111/apt.12279]
46 Whitfield K, Rambaldi A, Wetterslev J, Gluud C. Pentoxifylline 
for alcoholic hepatitis. Cochrane Database Syst Rev 2009; (4): 
CD007339 [PMID: 19821406 DOI: 10.1002/14651858.CD007339.
pub2]
47 O’Shea RS, Dasarathy S, McCullough AJ. Alcoholic liver disease. 
Am J Gastroenterol 2010; 105: 14-32; quiz 33 [PMID: 19904248 
DOI: 10.1038/ajg.2009.593]
48 Lee TD, Sadda MR, Mendler MH, Bottiglieri T, Kanel G, Mato 
JM, Lu SC. Abnormal hepatic methionine and glutathione 
metabolism in patients with alcoholic hepatitis. Alcohol Clin 
Exp Res 2004; 28: 173-181 [PMID: 14745316 DOI: 10.1097/01.
alc.0000108654.77178.03]
49 Lieber CS. S-Adenosyl-L-methionine and alcoholic liver disease in 
animal models: implications for early intervention in human beings. 
Alcohol 2002; 27: 173-177 [PMID: 12163146]
50 Karaa A, Thompson KJ, McKillop IH, Clemens MG, Schrum LW. 
S-adenosyl-L-methionine attenuates oxidative stress and hepatic 
stellate cell activation in an ethanol-LPS-induced fibrotic rat 
model. Shock 2008; 30: 197-205 [PMID: 18180699 DOI: 10.1097/
shk.0b013e318160f417]
51 Le MD, Enbom E, Traum PK, Medici V, Halsted CH, French 
SW. Alcoholic liver disease patients treated with S-adenosyl-L-
methionine: an in-depth look at liver morphologic data comparing 
pre and post treatment liver biopsies. Exp Mol Pathol 2013; 95: 
187-191 [PMID: 23886644 DOI: 10.1016/j.yexmp.2013.07.003]
52 Medici V, Virata MC, Peerson JM, Stabler SP, French SW, Gregory 
JF, Albanese A, Bowlus CL, Devaraj S, Panacek EA, Richards JR, 
Halsted CH. S-adenosyl-L-methionine treatment for alcoholic liver 
disease: a double-blinded, randomized, placebo-controlled trial. 
Alcohol Clin Exp Res 2011; 35: 1960-1965 [PMID: 22044287 DOI: 
10.1111/j.1530-0277.2011.01547.x]
53 Wagner M, Zollner G, Trauner M. Nuclear receptors in liver 
disease. Hepatology 2011; 53: 1023-1034 [PMID: 21319202 DOI: 
10.1002/hep.24148]
54 Rogers CQ, Ajmo JM, You M. Adiponectin and alcoholic fatty liver 
disease. IUBMB Life 2008; 60: 790-797 [PMID: 18709650 DOI: 
10.1002/iub.124]
55 Shen Z, Liang X, Rogers CQ, Rideout D, You M. Involvement 
of adiponectin-SIRT1-AMPK signaling in the protective action 
of rosiglitazone against alcoholic fatty liver in mice. Am J Physiol 
Gastrointest Liver Physiol 2010; 298: G364-G374 [PMID: 20007851 
DOI: 10.1152/ajpgi.00456.2009]
56 Liu J, Takase I, Hakucho A, Okamura N, Fujimiya T. Carvedilol 
attenuates the progression of alcohol fatty liver disease in rats. 
Alcohol Clin Exp Res 2012; 36: 1587-1599 [PMID: 22413959 DOI: 
10.1111/j.1530-0277.2012.01773.x]
57 Bergheim I, Guo L, Davis MA, Lambert JC, Beier JI, Duveau I, 
Luyendyk JP, Roth RA, Arteel GE. Metformin prevents alcohol-
induced liver injury in the mouse: Critical role of plasminogen 
activator inhibitor-1. Gastroenterology 2006; 130: 2099-2112 [PMID: 
16762632 DOI: 10.1053/j.gastro.2006.03.020]
58 Zhu Z, Jiang Z, Zhou J, Zhou D, Wang W, Zhao C, Zhen Z, Nanji 
AA. Involvement of insulin resistance in the protective effect of 
metformin against alcoholic liver injury. Alcohol Clin Exp Res 2014; 
38: 1510-1519 [PMID: 24797033 DOI: 10.1111/acer.12418]
59 Lieber CS. Microsomal ethanol-oxidizing system (MEOS): the first 
30 years (1968-1998)--a review. Alcohol Clin Exp Res 1999; 23: 
991-1007 [PMID: 10397283]
60 Lieber CS, Weiss DG, Groszmann R, Paronetto F, Schenker S. II. 
Veterans Affairs Cooperative Study of polyenylphosphatidylcholine 
in alcoholic liver disease. Alcohol Clin Exp Res 2003; 27: 1765-1772 
[PMID: 14634492 DOI: 10.1097/01.alc.0000093743.03049.80]
61 Gebhardt AC, Lucas D, Ménez JF, Seitz HK. Chlormethiazole 
inhibition of cytochrome P450 2E1 as assessed by chlorzoxazone 
hydroxylation in humans. Hepatology 1997; 26: 957-961 [PMID: 
9328319 DOI: 10.1002/hep.510260423]
62 Gouillon Z, Lucas D, Li J, Hagbjork AL, French BA, Fu P, Fang 
C, Ingelman-Sundberg M, Donohue TM, French SW. Inhibition of 
ethanol-induced liver disease in the intragastric feeding rat model by 
chlormethiazole. Proc Soc Exp Biol Med 2000; 224: 302-308 [PMID: 
10964266]
63 Kinde H, Bettey RL, Ardans A, Galey FD, Daft BM, Walker RL, 
Eklund MW, Byrd JW. Clostridium botulinum type-C intoxication 
associated with consumption of processed alfalfa hay cubes in 
horses. J Am Vet Med Assoc 1991; 199: 742-746 [PMID: 1955364]
64 Mencin A, Kluwe J, Schwabe RF. Toll-like receptors as targets in 
chronic liver diseases. Gut 2009; 58: 704-720 [PMID: 19359436 
DOI: 10.1136/gut.2008.156307]
65 Nanji AA, Khettry U, Sadrzadeh SM. Lactobacillus feeding reduces 
endotoxemia and severity of experimental alcoholic liver (disease). 
Proc Soc Exp Biol Med 1994; 205: 243-247 [PMID: 8171045]
66 Singh AK, Pandey SK, Naresh Kumar G. Pyrroloquinoline quinone-
secreting probiotic Escherichia coli Nissle 1917 ameliorates ethanol-
induced oxidative damage and hyperlipidemia in rats. Alcohol Clin 
Exp Res 2014; 38: 2127-2137 [PMID: 24930470 DOI: 10.1111/
acer.12456]
67 Vlachogiannakos J, Viazis N, Vasianopoulou P, Vafiadis I, 
Karamanolis DG, Ladas SD. Long-term administration of rifaximin 
improves the prognosis of patients with decompensated alcoholic 
cirrhosis. J Gastroenterol Hepatol 2013; 28: 450-455 [PMID: 
23216382 DOI: 10.1111/jgh.12070]
68 Clot P, Tabone M, Aricò S, Albano E. Monitoring oxidative damage 
in patients with liver cirrhosis and different daily alcohol intake. Gut 
1994; 35: 1637-1643 [PMID: 7828989]
69 Gutiérrez-Ruiz MC, Bucio L, Correa A, Souza V, Hernández E, 
Gómez-Quiroz LE, Kershenobich D. Metadoxine prevents damage 
produced by ethanol and acetaldehyde in hepatocyte and hepatic 
stellate cells in culture. Pharmacol Res 2001; 44: 431-436 [PMID: 
11712874 DOI: 10.1006/phrs.2001.0883]
70 Muntoni S, Rojkind M, Muntoni S. Colchicine reduces procollagen 
III and increases pseudocholinesterase in chronic liver disease. 
World J Gastroenterol 2010; 16: 2889-2894 [PMID: 20556834 DOI: 
10.3748/wjg.v16.i23.2889]
71 Carmichael FJ, Orrego H, Saldivia V, Israel Y. Effect of 
propylthiouracil on the ethanol-induced increase in liver oxygen 
consumption in awake rats. Hepatology 1993; 18: 415-421 [PMID: 
8340071 DOI: 10.1002/hep.1840180228]
14 January 7, 2016|Volume 22|Issue 1|WJG|www.wjgnet.com
72 Dureja P, Lucey MR. The place of liver transplantation in the 
treatment of severe alcoholic hepatitis. J Hepatol 2010; 52: 759-764 
[PMID: 20347501 DOI: 10.1016/j.jhep.2009.12.021]
73 Pageaux GP, Bismuth M, Perney P, Costes V, Jaber S, Possoz P, 
Fabre JM, Navarro F, Blanc P, Domergue J, Eledjam JJ, Larrey D. 
Alcohol relapse after liver transplantation for alcoholic liver disease: 
does it matter? J Hepatol 2003; 38: 629-634 [PMID: 12713874]
74 Tang H, Boulton R, Gunson B, Hubscher S, Neuberger J. Patterns 
of alcohol consumption after liver transplantation. Gut 1998; 43: 
140-145 [PMID: 9771419]
75 Dumortier J, Guillaud O, Adham M, Boucaud C, Delafosse B, 
Bouffard Y, Paliard P, Scoazec JY, Boillot O. Negative impact of de 
novo malignancies rather than alcohol relapse on survival after liver 
transplantation for alcoholic cirrhosis: a retrospective analysis of 305 
patients in a single center. Am J Gastroenterol 2007; 102: 1032-1041 
[PMID: 17313502 DOI: 10.1111/j.1572-0241.2007.01079.x]
76 Burra P, Senzolo M, Adam R, Delvart V, Karam V, Germani 
G, Neuberger J. Liver transplantation for alcoholic liver disease 
in Europe: a study from the ELTR (European Liver Transplant 
Registry). Am J Transplant 2010; 10: 138-148 [PMID: 19951276 
DOI: 10.1111/j.1600-6143.2009.02869.x]
77 Zanus G, Carraro A, Vitale A, Gringeri E, D’Amico F, Valmasoni 
M, D’Amico FE, Brolese A, Boccagni P, Neri D, Srsen N, Burra P, 
Feltracco P, Bonsignore P, Scopelliti M, Cillo U. Alcohol abuse and 
de novo tumors in liver transplantation. Transplant Proc 2009; 41: 
1310-1312 [PMID: 19460548 DOI: 10.1016/j.transproceed.2009.03.
055]
78 Tomé S, Martinez-Rey C, González-Quintela A, Gude F, Brage A, 
Otero E, Abdulkader I, Forteza J, Bustamante M, Varo E. Influence 
of superimposed alcoholic hepatitis on the outcome of liver 
transplantation for end-stage alcoholic liver disease. J Hepatol 2002; 
36: 793-798 [PMID: 12044530]
79 Lucey MR, Brown KA, Everson GT, Fung JJ, Gish R, Keeffe 
EB, Kneteman NM, Lake JR, Martin P, McDiarmid SV, Rakela J, 
Shiffman ML, So SK, Wiesner RH. Minimal criteria for placement 
of adults on the liver transplant waiting list: a report of a national 
conference organized by the American Society of Transplant 
Physicians and the American Association for the Study of Liver 
Diseases. Liver Transpl Surg 1997; 3: 628-637 [PMID: 9404965]
80 Westphal JF, Brogard JM. Drug administration in chronic liver 
disease. Drug Saf 1997; 17: 47-73 [PMID: 9258630]
81 French SW. The importance of CYP2E1 in the pathogenesis 
of alcoholic liver disease and drug toxicity and the role of the 
proteasome. Subcell Biochem 2013; 67: 145-164 [PMID: 23400920 
DOI: 10.1007/978-94-007-5881-0_4]
82 Spengler EK, Dunkelberg J, Schey R. Alcoholic hepatitis: current 
management. Dig Dis Sci 2014; 59: 2357-2366 [PMID: 24798996 
DOI: 10.1007/s10620-014-3173-8]
83 Naveau S, Chollet-Martin S, Dharancy S, Mathurin P, Jouet P, 
Piquet MA, Davion T, Oberti F, Broët P, Emilie D. A double-
blind randomized controlled trial of infliximab associated with 
prednisolone in acute alcoholic hepatitis. Hepatology 2004; 39: 
1390-1397 [PMID: 15122768 DOI: 10.1002/hep.20206]
84 Brackett CC. Clarifying metformin’s role and risks in liver 
dysfunction. J Am Pharm Assoc (2003) 2010; 50: 407-410 [PMID: 
20452916 DOI: 10.1331/JAPhA.2010.08090]
85 Cortez-Pinto H, Alexandrino P, Camilo ME, Gouveia-Oliveira A, 
Santos PM, Alves MM, Moura MC. Lack of effect of colchicine in 
alcoholic cirrhosis: final results of a double blind randomized trial. 
Eur J Gastroenterol Hepatol 2002; 14: 377-381 [PMID: 11943949]
86 Seeff LB, Lindsay KL, Bacon BR, Kresina TF, Hoofnagle JH. 
Complementary and alternative medicine in chronic liver disease. 
Hepatology 2001; 34: 595-603 [PMID: 11526548 DOI: 10.1053/
jhep.2001.27445]
87 Strader DB, Bacon BR, Lindsay KL, La Brecque DR, Morgan 
T, Wright EC, Allen J, Khokar MF, Hoofnagle JH, Seeff LB. Use 
of complementary and alternative medicine in patients with liver 
disease. Am J Gastroenterol 2002; 97: 2391-2397 [PMID: 12358262 
DOI: 10.1111/j.1572-0241.2002.05993.x]
88 Arteel GE, Uesugi T, Bevan LN, Gäbele E, Wheeler MD, McKim 
SE, Thurman RG. Green tea extract protects against early alcohol-
induced liver injury in rats. Biol Chem 2002; 383: 663-670 [PMID: 
12033455 DOI: 10.1515/bc.2002.068]
89 Higdon JV, Frei B. Tea catechins and polyphenols: health effects, 
metabolism, and antioxidant functions. Crit Rev Food Sci Nutr 2003; 
43: 89-143 [PMID: 12587987 DOI: 10.1080/10408690390826464]
90 Tedeschi E, Suzuki H, Menegazzi M. Antiinflammatory action of 
EGCG, the main component of green tea, through STAT-1 inhibition. 
Ann N Y Acad Sci 2002; 973: 435-437 [PMID: 12485906]
91 Lambert JD, Yang CS. Mechanisms of cancer prevention by tea 
constituents. J Nutr 2003; 133: 3262S-3267S [PMID: 14519824]
92 Kim JJ, Tan Y, Xiao L, Sun YL, Qu X. Green tea polyphenol 
epigallocatechin-3-gallate enhance glycogen synthesis and inhibit 
lipogenesis in hepatocytes. Biomed Res Int 2013; 2013: 920128 
[PMID: 24066304 DOI: 10.1155/2013/920128]
93 Kaviarasan S, Sundarapandiyan R, Anuradha CV. Epigallocatechin 
gallate, a green tea phytochemical, attenuates alcohol-induced 
hepatic protein and lipid damage. Toxicol Mech Methods 2008; 18: 
645-652 [PMID: 20020850 DOI: 10.1080/15376510701884985]
94 Yuan G, Gong Z, Zhou X, Zhangq P, Sun X, Li X. Epigallocatechin-
3-Gallate Ameliorates Alcohol-Induced Liver Injury in Rats. Int J 
Mol Sci 2006; 7: 204 [DOI: 10.3390/i7070204]
95 Yun JW, Kim YK, Lee BS, Kim CW, Hyun JS, Baik JH, Kim JJ, 
Kim BH. Effect of dietary epigallocatechin-3-gallate on cytochrome 
P450 2E1-dependent alcoholic liver damage: enhancement of fatty 
acid oxidation. Biosci Biotechnol Biochem 2007; 71: 2999-3006 
[PMID: 18071271 DOI: 10.1271/bbb.70403]
96 Nussler AK, Hao L, Knobeloch D, Yao P, Nussler NC, Wang Z, 
Liu L, Ehnert S. Protective role of HO-1 for alcohol-dependent 
liver damage. Dig Dis 2010; 28: 792-798 [PMID: 21525764 DOI: 
10.1159/000324287]
97 Kroll DJ, Shaw HS, Oberlies NH. Milk thistle nomenclature: why 
it matters in cancer research and pharmacokinetic studies. Integr 
Cancer Ther 2007; 6: 110-119 [PMID: 17548790 DOI: 10.1177/153
4735407301825]
98 Comoglio A, Tomasi A, Malandrino S, Poli G, Albano E. 
Scavenging effect of silipide, a new silybin-phospholipid complex, 
on ethanol-derived free radicals. Biochem Pharmacol 1995; 50: 
1313-1316 [PMID: 7488251]
99 El-Kamary SS, Shardell MD, Abdel-Hamid M, Ismail S, El-Ateek 
M, Metwally M, Mikhail N, Hashem M, Mousa A, Aboul-Fotouh A, 
El-Kassas M, Esmat G, Strickland GT. A randomized controlled trial 
to assess the safety and efficacy of silymarin on symptoms, signs 
and biomarkers of acute hepatitis. Phytomedicine 2009; 16: 391-400 
[PMID: 19303273 DOI: 10.1016/j.phymed.2009.02.002]
100 Lieber CS, Leo MA, Cao Q, Ren C, DeCarli LM. Silymarin retards 
the progression of alcohol-induced hepatic fibrosis in baboons. J 
Clin Gastroenterol 2003; 37: 336-339 [PMID: 14506392]
101 Zhang W, Hong R, Tian T. Silymarin’s Protective Effects and 
Possible Mechanisms on Alcoholic Fatty Liver for Rats. Biomol 
Ther (Seoul) 2013; 21: 264-269 [PMID: 24244810 DOI: 10.4062/
biomolther.2013.020]
102 IDel Prete A, Scalera A, Iadevaia MD, Miranda A, Zulli C, Gaeta 
L, Tuccillo C, Federico A, Loguercio C. Herbal products: benefits, 
limits, and applications in chronic liver disease. Evid Based 
Complement Alternat Med 2012; 2012: 837939 [PMID: 22991573 
DOI: 10.1155/2012/837939]
103 Purohit V, Abdelmalek MF, Barve S, Benevenga NJ, Halsted CH, 
Kaplowitz N, Kharbanda KK, Liu QY, Lu SC, McClain CJ, Swanson 
C, Zakhari S. Role of S-adenosylmethionine, folate, and betaine in 
the treatment of alcoholic liver disease: summary of a symposium. 
Am J Clin Nutr 2007; 86: 14-24 [PMID: 17616758]
104 Kharbanda KK, Mailliard ME, Baldwin CR, Beckenhauer 
HC, Sorrell MF, Tuma DJ. Betaine attenuates alcoholic steatosis 
by restoring phosphatidylcholine generation via the phospha-
tidylethanolamine methyltransferase pathway. J Hepatol 2007; 46: 
314-321 [PMID: 17156888 DOI: 10.1016/j.jhep.2006.08.024]
105 Maiti K, Mukherjee K, Gantait A, Saha BP, Mukherjee PK. 
Curcumin-phospholipid complex: Preparation, therapeutic evaluation 
and pharmacokinetic study in rats. Int J Pharm 2007; 330: 155-163 
1 January 7, 2016|Volume 22|Issue 1|WJG|www.wjgnet.com
[PMID: 17112692 DOI: 10.1016/j.ijpharm.2006.09.025]
106 Kharbanda KK, Todero SL, King AL, Osna NA, McVicker BL, 
Tuma DJ, Wisecarver JL, Bailey SM. Betaine treatment attenuates 
chronic ethanol-induced hepatic steatosis and alterations to the 
mitochondrial respiratory chain proteome. Int J Hepatol 2012; 2012: 
962183 [PMID: 22187660 DOI: 10.1155/2012/962183]
107 Shi QZ, Wang LW, Zhang W, Gong ZJ. Betaine inhibits toll-like 
receptor 4 expression in rats with ethanol-induced liver injury. World 
J Gastroenterol 2010; 16: 897-903 [PMID: 20143470]
108 Li YJ, Chen J, Li Y, Li Q, Zheng YF, Fu Y, Li P. Screening and 
characterization of natural antioxidants in four Glycyrrhiza species 
by liquid chromatography coupled with electrospray ionization 
quadrupole time-of-flight tandem mass spectrometry. J Chromatogr 
A 2011; 1218: 8181-8191 [PMID: 21968349 DOI: 10.1016/
j.chroma.2011.09.030]
109 Gwak GY, Moon TG, Lee DH, Yoo BC. Glycyrrhizin attenuates 
HMGB1-induced hepatocyte apoptosis by inhibiting the p38-
dependent mitochondrial pathway. World J Gastroenterol 2012; 18: 
679-684 [PMID: 22363140 DOI: 10.3748/wjg.v18.i7.679]
110 Fiore C, Eisenhut M, Krausse R, Ragazzi E, Pellati D, Armanini D, 
Bielenberg J. Antiviral effects of Glycyrrhiza species. Phytother Res 
2008; 22: 141-148 [PMID: 17886224 DOI: 10.1002/ptr.2295]
111 Wang CY, Kao TC, Lo WH, Yen GC. Glycyrrhizic acid and 
18β-glycyrrhetinic acid modulate lipopolysaccharide-induced 
inflammatory response by suppression of NF-κB through PI3K 
p110δ and p110γ inhibitions. J Agric Food Chem 2011; 59: 
7726-7733 [PMID: 21644799 DOI: 10.1021/jf2013265]
112 Thiyagarajan P, Chandrasekaran CV, Deepak HB, Agarwal A. 
Modulation of lipopolysaccharide-induced pro-inflammatory 
mediators by an extract  of  Glycyrrhiza glabra and i ts 
phytoconstituents. Inflammopharmacology 2011; 19: 235-241 
[PMID: 21328091 DOI: 10.1007/s10787-011-0080-x]
113 Li XL, Zhou AG. Evaluation of the immunity activity of glycyrrhizin 
in AR mice. Molecules 2012; 17: 716-727 [PMID: 22241467 DOI: 
10.3390/molecules17010716]
114 Wang J, Guo J, Liu S. [Inhibitory effect of glycyrrhizin on NF-
kappa B binding activity in CCl4 plus ethanol induced liver cirrhosis 
in rats]. Zhonghua Gan Zang Bing Za Zhi 1999; 7: 42-43 [PMID: 
10366987]
115 Wang JY, Guo JS, Li H, Liu SL, Zern MA. Inhibitory effect of 
glycyrrhizin on NF-kappaB binding activity in CCl4- plus ethanol-
induced liver cirrhosis in rats. Liver 1998; 18: 180-185 [PMID: 
9716228]
116 Arase Y, Ikeda K, Murashima N, Chayama K, Tsubota A, Koida 
I, Suzuki Y, Saitoh S, Kobayashi M, Kumada H. The long term 
efficacy of glycyrrhizin in chronic hepatitis C patients. Cancer 1997; 
79: 1494-1500 [PMID: 9118029]
117 Huu Tung N, Uto T, Morinaga O, Kim YH, Shoyama Y. 
Pharmacological effects of ginseng on liver functions and diseases: 
a minireview. Evid Based Complement Alternat Med 2012; 2012: 
173297 [PMID: 22997528 DOI: 10.1155/2012/173297]
118 Cho WC, Chung WS, Lee SK, Leung AW, Cheng CH, Yue KK. 
Ginsenoside Re of Panax ginseng possesses significant antioxidant 
and antihyperlipidemic efficacies in streptozotocin-induced diabetic 
rats. Eur J Pharmacol 2006; 550: 173-179 [PMID: 17027742 DOI: 
10.1016/j.ejphar.2006.08.056]
119 Yokozawa T, Kobayashi T, Oura H, Kawashima Y. Hyperlipemia-
improving effects of ginsenoside-Rb2 in streptozotocin-diabetic rats. 
Chem Pharm Bull (Tokyo) 1985; 33: 3893-3898 [PMID: 4092288]
120 Hou YL, Tsai YH, Lin YH, Chao JC. Ginseng extract and 
ginsenoside Rb1 attenuate carbon tetrachloride-induced liver fibrosis 
in rats. BMC Complement Altern Med 2014; 14: 415 [PMID: 
25344394 DOI: 10.1186/1472-6882-14-415]
121 Song SB, Tung NH, Quang TH, Ngan NT, Kim KE, Kim YH. 
Inhibition of TNF-α-mediated NF-κB Transcriptional Activity in 
HepG2 Cells by Dammarane-type Saponins from Panax ginseng 
Leaves. J Ginseng Res 2012; 36: 146-152 [PMID: 23717114 DOI: 
10.5142/jgr.2012.36.2.146]
122 Yuan HD, Kim SJ, Quan HY, Kim DY, Kim GW, Chung SH. 
Ginsenoside Re attenuates alcoholic fatty liver disease via 
regulation of AMPK and MAPK pathways in alcohol-fed ICR mice. 
Proceedings of the Proceedings of the Spring International Ginseng 
Conference. Jeju, Korea: Spring, 2012: 114
123 Han JY, Lee S, Yang JH, Kim S, Sim J, Kim MG, Jeong TC, 
Ku SK, Cho IJ, Ki SH. Korean Red Ginseng attenuates ethanol-
induced steatosis and oxidative stress via AMPK/Sirt1 activation. J 
Ginseng Res 2015; 39: 105-115 [PMID: 26045683 DOI: 10.1016/
j.jgr.2014.09.001]
124 Hong M, Kim SW, Han SH, Kim DJ, Suk KT, Kim YS, Kim MJ, 
Kim MY, Baik SK, Ham YL. Probiotics (Lactobacillus rhamnosus 
R0011 and acidophilus R0052) reduce the expression of toll-like 
receptor 4 in mice with alcoholic liver disease. PLoS One 2015; 10: 
e0117451 [PMID: 25692549 DOI: 10.1371/journal.pone.0117451]
125 Kim MS, Lee KT, Iseli TJ, Hoy AJ, George J, Grewal T, Roufogalis 
BD. Compound K modulates fatty acid-induced lipid droplet 
formation and expression of proteins involved in lipid metabolism in 
hepatocytes. Liver Int 2013; 33: 1583-1593 [PMID: 23998390 DOI: 
10.1111/liv.12287]
126 Anuradha CV, Ravikumar P. Restoration on tissue antioxidants 
by fenugreek seeds (Trigonella Foenum Graecum) in alloxan-
diabetic rats. Indian J Physiol Pharmacol 2001; 45: 408-420 [PMID: 
11883146]
127 Kochhar A, Nagi M. Effect of supplementation of traditional 
medicinal plants on blood glucose in non-insulin-dependent 
diabetics: a pilot study. J Med Food 2005; 8: 545-549 [PMID: 
16379570 DOI: 10.1089/jmf.2005.8.545]
128 Shang M, Cai S, Han J, Li J, Zhao Y, Zheng J, Namba T, Kadota S, 
Tezuka Y, Fan W. [Studies on flavonoids from Fenugreek (Trigonella 
foenumgraecum L.)]. Zhongguo Zhong Yao Za Zhi 1998; 23: 614-66, 
639 [PMID: 11599360]
129 Kaviarasan S, Ramamurty N, Gunasekaran P, Varalakshmi E, 
Anuradha CV. Fenugreek (Trigonella foenum graecum) seed extract 
prevents ethanol-induced toxicity and apoptosis in Chang liver 
cells. Alcohol Alcohol 2006; 41: 267-273 [PMID: 16574673 DOI: 
10.1093/alcalc/agl020]
130 Nickel T, Hanssen H, Sisic Z, Pfeiler S, Summo C, Schmauss 
D, Hoster E, Weis M. Immunoregulatory effects of the flavonol 
quercetin in vitro and in vivo. Eur J Nutr 2011; 50: 163-172 [PMID: 
20652710 DOI: 10.1007/s00394-010-0125-8]
131 Tang Y, Gao C, Xing M, Li Y, Zhu L, Wang D, Yang X, Liu L, Yao P. 
Quercetin prevents ethanol-induced dyslipidemia and mitochondrial 
oxidative damage. Food Chem Toxicol 2012; 50: 1194-1200 [PMID: 
22365892 DOI: 10.1016/j.fct.2012.02.008]
132 Kaviarasan S, Viswanathan P, Anuradha CV. Fenugreek seed 
(Trigonella foenum graecum) polyphenols inhibit ethanol-induced 
collagen and lipid accumulation in rat liver. Cell Biol Toxicol 2007; 
23: 373-383 [PMID: 17453353 DOI: 10.1007/s10565-007-9000-7]
133 Bao W, Li K, Rong S, Yao P, Hao L, Ying C, Zhang X, Nussler A, 
Liu L. Curcumin alleviates ethanol-induced hepatocytes oxidative 
damage involving heme oxygenase-1 induction. J Ethnopharmacol 
2010;  128 :  549-553 [PMID: 20080166 DOI:  10.1016/
j.jep.2010.01.029]
134 Samuhasaneeto S, Thong-Ngam D, Kulaputana O, Suyasunanont 
D, Klaikeaw N. Curcumin decreased oxidative stress, inhibited NF-
kappaB activation, and improved liver pathology in ethanol-induced 
liver injury in rats. J Biomed Biotechnol 2009; 2009: 981963 [PMID: 
19606259 DOI: 10.1155/2009/981963]
135 Nanji AA, Jokelainen K, Tipoe GL, Rahemtulla A, Thomas P, 
Dannenberg AJ. Curcumin prevents alcohol-induced liver disease in 
rats by inhibiting the expression of NF-kappa B-dependent genes. 
Am J Physiol Gastrointest Liver Physiol 2003; 284: G321-G327 
[PMID: 12388178 DOI: 10.1152/ajpgi.00230.2002]
136 Lee HI, McGregor RA, Choi MS, Seo KI, Jung UJ, Yeo J, Kim 
MJ, Lee MK. Low doses of curcumin protect alcohol-induced liver 
damage by modulation of the alcohol metabolic pathway, CYP2E1 
and AMPK. Life Sci 2013; 93: 693-699 [PMID: 24063989 DOI: 
10.1016/j.lfs.2013.09.014]
137 Rong S, Zhao Y, Bao W, Xiao X, Wang D, Nussler AK, Yan H, Yao 
P, Liu L. Curcumin prevents chronic alcohol-induced liver disease 
involving decreasing ROS generation and enhancing antioxidative 
16 January 7, 2016|Volume 22|Issue 1|WJG|www.wjgnet.com
capacity. Phytomedicine 2012; 19: 545-550 [PMID: 22445643 DOI: 
10.1016/j.phymed.2011.12.006]
138 Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. 
Bioavailability of curcumin: problems and promises. Mol Pharm 
2007; 4: 807-818 [PMID: 17999464 DOI: 10.1021/mp700113r]
139 Wang L, Wang BE, Wang J, Xiao PG, Tan XH. Herbal compound 
861 regulates mRNA expression of collagen synthesis- and 
degradation-related genes in human hepatic stellate cells. World J 
Gastroenterol 2008; 14: 1790-1794 [PMID: 18350612]
140 You H, Wang B, Wang T. [Proliferation and apoptosis of hepatic 
stellate cells and effects of compound 861 on liver fibrosis]. 
Zhonghua Gan Zang Bing Za Zhi 2000; 8: 78-80 [PMID: 10861108]
141 Yin C, Ma H, Wang A, Ma X, Jia J, Wang B. [Effect of compound 
861 on tissue inhibitor of metalloprotenase 1 gene expression of 
HSC-T6 cells]. Zhonghua Gan Zang Bing Za Zhi 2002; 10: 197-199 
[PMID: 12113678]
142 Baoen W, Tailing W, Jidong J, Hong M, Zhongping D, Xinmin 
L, Jia L, Aimin W, Linxue Q. Experimental and clinical study on 
inhibition and reversion of Liver fibrosis with integrated Chinese and 
western medicine. CJIM 1999; 5: 6-11 [DOI: 10.1007/BF02934179]
143 Yin SS, Wang BE, Wang TL, Jia JD, Qian LX. [The effect of Cpd 
861 on chronic hepatitis B related fibrosis and early cirrhosis: 
a randomized, double blind, placebo controlled clinical trial]. 
Zhonghua Gan Zang Bing Za Zhi 2004; 12: 467-470 [PMID: 
15329205]
144 Shimizu I, Ma YR, Mizobuchi Y, Liu F, Miura T, Nakai Y, Yasuda 
M, Shiba M, Horie T, Amagaya S, Kawada N, Hori H, Ito S. Effects 
of Sho-saiko-to, a Japanese herbal medicine, on hepatic fibrosis in 
rats. Hepatology 1999; 29: 149-160 [PMID: 9862861 DOI: 10.1002/
hep.510290108]
145 Cohen MR. Herbal and complementary and alternative medicine 
therapies for liver disease. A focus on Chinese traditional medicine 
in hepatitis C virus. Clin Liver Dis 2001; 5: 461-78, vii [PMID: 
11385972]
146 Dhiman RK, Chawla YK. Herbal medicines for liver diseases. Dig 
Dis Sci 2005; 50: 1807-1812 [PMID: 16187178 DOI: 10.1007/
s10620-005-2942-9]
147 Schuppan D, Jia JD, Brinkhaus B, Hahn EG. Herbal products for 
liver diseases: a therapeutic challenge for the new millennium. 
Hepatology 1999; 30: 1099-1104 [PMID: 10498665 DOI: 10.1002/
hep.510300437]
148 Mitra SK, Varma SR, Godavarthi A, Nandakumar KS. Liv.52 
regulates ethanol induced PPARgamma and TNF alpha expression in 
HepG2 cells. Mol Cell Biochem 2008; 315: 9-15 [PMID: 18449625 
DOI: 10.1007/s11010-008-9782-9]
149 Huseini HF, Alavian SM, Heshmat R, Heydari MR, Abolmaali K. 
The efficacy of Liv-52 on liver cirrhotic patients: a randomized, 
double-blind, placebo-controlled first approach. Phytomedicine 
2005; 12: 619-624 [PMID: 16194047]
150 Mao YM, Zeng MD, Chen Y, Chen CW, Fu QC, Cai X, Wu SM, 
Chen YG, Sun Y, Li J, Sui YH, Zhao W, Lu LG, Cao AP, Chen HZ. 
[Magnesium isoglycyrrhizinate in the treatment of chronic liver 
diseases: a randomized, double-blind, multi-doses, active drug 
controlled, multi-center study]. Zhonghua Gan Zang Bing Za Zhi 
2009; 17: 847-851 [PMID: 19958646]
151 Xiao ZW, Zhang W, Ma L, Qiu ZW. Therapeutic effect of 
magnesium isoglycyrrhizinate in rats on lung injury induced by 
paraquat poisoning. Eur Rev Med Pharmacol Sci 2014; 18: 311-320 
[PMID: 24563429]
152 Zhao J, Wan XY, Luo M, Chen TS, He P. Antifibrotic effects of 
glycyrrhizin and matrine in vitro and in vivo. Biomedicine Preventive 
Nutrition 2012; 2: 132-137 [DOI: 10.1016/j.bionut.2011.12.006]
153 Testino G, Leone S, Ansaldi F, Borro P. Silymarin and S-adenosyl-
L-methionine (SAMe): two promising pharmacological agents in 
case of chronic alcoholic hepathopathy. A review and a point of view. 
Minerva Gastroenterol Dietol 2013; 59: 341-356 [PMID: 24212353]
154 Stickel F, Patsenker E, Schuppan D. Herbal hepatotoxicity. J 
Hepatol 2005; 43: 901-910 [PMID: 16171893 DOI: 10.1016/
j.jhep.2005.08.002]
155 Nakagawa A, Yamaguchi T, Takao T, Amano H. [Five cases of 
drug-induced pneumonitis due to Sho-saiko-to or interferon-alpha 
or both]. Nihon Kyobu Shikkan Gakkai Zasshi 1995; 33: 1361-1366 
[PMID: 8821988]
156 DiCenzo R, Shelton M, Jordan K, Koval C, Forrest A, Reichman R, 
Morse G. Coadministration of milk thistle and indinavir in healthy 
subjects. Pharmacotherapy 2003; 23: 866-870 [PMID: 12885100]
157 Singal AK, Anand BS. Recent trends in the epidemiology of 
alcoholic liver disease. Clinical Liver Disease 2013; 2: 53-56 [DOI: 
10.1002/cld.168]
158 Moghe A, Joshi-Barve S, Ghare S, Gobejishvili L, Kirpich I, 
McClain CJ, Barve S. Histone modifications and alcohol-induced 
liver disease: are altered nutrients the missing link? World J 
Gastroenterol 2011; 17: 2465-2472 [PMID: 21633651 DOI: 
10.3748/wjg.v17.i20.2465]
159 You M, Crabb DW. Molecular mechanisms of alcoholic fatty liver: 
role of sterol regulatory element-binding proteins. Alcohol 2004; 34: 
39-43 [PMID: 15670664 DOI: 10.1016/j.alcohol.2004.07.004]
160 Carithers RL, Herlong HF, Diehl AM, Shaw EW, Combes B, 
Fallon HJ, Maddrey WC. Methylprednisolone therapy in patients 
with severe alcoholic hepatitis. A randomized multicenter trial. Ann 
Intern Med 1989; 110: 685-690 [PMID: 2648927]
161 De BK, Gangopadhyay S, Dutta D, Baksi SD, Pani A, Ghosh P. 
Pentoxifylline versus prednisolone for severe alcoholic hepatitis: 
a randomized controlled trial. World J Gastroenterol 2009; 15: 
1613-1619 [PMID: 19340904]
162 Frezza M, Surrenti C, Manzillo G, Fiaccadori F, Bortolini M, Di 
Padova C. Oral S-adenosylmethionine in the symptomatic treatment 
of intrahepatic cholestasis. A double-blind, placebo-controlled study. 
Gastroenterology 1990; 99: 211-215 [PMID: 2188871]
163 Fischer M, You M, Matsumoto M, Crabb DW. Peroxisome 
proliferator-activated receptor alpha (PPARalpha) agonist treatment 
reverses PPARalpha dysfunction and abnormalities in hepatic 
lipid metabolism in ethanol-fed mice. J Biol Chem 2003; 278: 
27997-28004 [PMID: 12791698 DOI: 10.1074/jbc.M302140200]
164 Kong L, Ren W, Li W, Zhao S, Mi H, Wang R, Zhang Y, Wu W, 
Nan Y, Yu J. Activation of peroxisome proliferator activated receptor 
alpha ameliorates ethanol induced steatohepatitis in mice. Lipids 
Health Dis 2011; 10: 246 [PMID: 22208561 DOI: 10.1186/1476-511
x-10-246]
165 Soylu AR, Altaner S, Aydodu N, Basaran UN, Tarcin O, Gedik N, 
Umit H, Tezel A, Ture M, Kutlu K, Kaymak K. Effects of vitamins 
E and C supplementation on hepatic glutathione peroxidase activity 
and tissue injury associated with ethanol ingestion in malnourished 
rats. Curr Ther Res Clin Exp 2006; 67: 118-137 [PMID: 24678089 
DOI: 10.1016/j.curtheres.2006.04.007]
166 Wang FS, Fan JG, Zhang Z, Gao B, Wang HY. The global burden 
of liver disease: the major impact of China. Hepatology 2014; 60: 
2099-2108 [PMID: 25164003 DOI: 10.1002/hep.27406]
P- Reviewer: Wan JB    S- Editor: Kong JX 
L- Editor: Filipodia A    E- Editor: Wang CH 
